

AD_____

Award Number: DAMD17-99-1-9244

TITLE: Development of Pro-Peptide Immunotherapy for Breast
Cancer

PRINCIPAL INVESTIGATOR: Wei-Zen Wei, Ph.D.

CONTRACTING ORGANIZATION: Wayne State University
Detroit, MI 48201

REPORT DATE: July 2003

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20040618 192

REPORT DOCUMENTATION PAGEForm Approved
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE July 2003	3. REPORT TYPE AND DATES COVERED Final (1 Jul 1999 - 30 Jun 2003)	
4. TITLE AND SUBTITLE Development of Pro-Peptide Immunotherapy for Breast Cancer			5. FUNDING NUMBERS DAMD17-99-1-9244	
6. AUTHOR(S) Wei-Zen Wei, Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Wayne State University Detroit, MI 48201 E-Mail: wei@karmanos.org			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited			12b. DISTRIBUTION CODE	
13. ABSTRACT (Maximum 200 Words) The proposed study will test the hypothesis that solid tumors can be eliminated by immunizing the host with specific foreign peptides and by delivering these peptides to the tumors in the form of pro-peptides which are activated at the tumor sites. This immunotherapy approach takes advantage of the potent tumor destruction capacity of T cells and is independent of self tumor-antigens. The therapeutic peptides will be conjugated to glucuronide through a spacer to form pro-peptides which will have increased aqueous solubility and no longer bind the MHC. Glucuronidase liberated by the tumor cells and tumor infiltrating inflammatory cells is expected to convert the pro-peptides to the active, MHC binding peptides in the vicinity of the tumor mass. The potent peptide specific CTL <i>in vivo</i> are expected to kill the tumor cells or the stromal/endothelial cells surrounding the tumor bed when these cells are marked on their MHC by the liberated peptides, achieving the goal of immunotherapy with foreign peptides. The technical objectives are to (1) Establish an <i>in vitro</i> assay to measure tumor growth inhibition by peptide specific T cells and pro-peptides, (2) synthesize and test the activity of pro-peptides to be activated by β -glucuronidase at the tumor site and (3) Develop human anti-MP58 CTL line and measure pro-peptide activity with anti-MP58 CTL.				
14. SUBJECT TERMS Breast Cancer			15. NUMBER OF PAGES 28	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

NSN 7540-01-280-5500

Standard Form 298 (Rev. 2-89)
Prescribed by ANSI Std. Z39-18
298-102

Table of Contents

Cover.....	1
SF 298.....	2
Table of Contents.....	3
Introduction.....	4
Body.....	4
Key Research Accomplishments.....	6
Reportable Outcomes.....	6
Conclusions.....	6
Appendices.....	A-C

INTRODUCTION

This is the revised final report for DAMD17-99-1-9244 "Development of Pro-Peptide Immunotherapy for Breast Cancer". This three year project was extended to the fourth year to verify results in Task 3 and test lipoprotein conjugation of candidate peptides.

The proposed study was to test the novel hypothesis that solid tumors can be eliminated by immunizing the host with foreign peptides and by delivering these peptides to the tumors in the form of pro-peptides which are activated at the tumor sites. Specifically,

- Task 1 Establish an in vitro assay to measure tumor growth inhibition by peptide specific T cells and pro-peptides
- Task 2 Synthesize and test the activity of pro-peptides to be activated by β -glucuronidase at the tumor site
 - (A) Synthesis of glucuronide derivatives of Flu peptide MP-58 GILGFVFTL presented by human HLA-A2.1.
 - (B) Measurement of peptide and pro-peptide binding to MHC.
- Task 3 Develop human anti-MP58 CTL line and measure pro-peptide activity with anti-MP58 CTL.

BODY

Task 1 Establish an in vitro assay to measure tumor growth inhibition by peptide specific T cells and pro-peptides. Results from this task were described in 2000 annual report and have been published (Appendix A).

A three dimensional tumor growth system which mimics tumor growth *in vivo* was used to measure the activity of peptide specific CTL against tumor cells loaded exogenously with the same antigenic peptide. D2F2 tumor cells and CTL specific for β -gal peptide p876 TPHPARIGL were suspended together in 1 μ l of collagen and embedded in collagen gel in 24 well plate. p876 at 5 or 20 μ g/ml was added to the gel when the cells started to grow from the bolus after overnight culture. Complete inhibition of tumor growth was observed in the wells with added p876, indicating that p876 diffused through the gel to load the cells in the growing tumor which became a target of anti-p876 CTL. D2F2 cells embedded with anti-p876 CTL, but without exogenous peptide grew progressively.

To test whether CTL can migrate through the matrix to destroy the target tumor, D2F2 mammary tumor cells were embedded in the collagen, incubated overnight and CTL were added on top of the gel. Approximately 20-40% of CTL migrated through the collagen in 18 hrs and floating T cells were removed. Peptide p876 at 5 or 20 μ g/ml was added and complete disintegration of the tumor boluses was observed after 5 days of culture, further supporting the principle of delivering exogenous peptide to mark the tumor for T cell destruction.

Task 2 Synthesize and test the activity of pro-peptides to be activated by β -glucuronidase. Results from this task were described in 2001 and 2002 annual reports and have been published (Appendix B).

We tested two methods for synthesis of prodrugs of MP58 **2a** (see appendix B) activated by beta-glucuronidase and comprising a self-immolative 3-nitrobenzyloxycarbonyl moiety were investigated. Reaction of beta-glucuronic acid glycoside of 4-hydroxy-3-nitrobenzyl alcohol (**3**)

with N,N'-disuccinimidyl carbonate (DSC) followed by conjugation with AlaOme, Gly, Thr, Phe-Leu, or Leu-Arg gave carbamates **4a-4f**. Deacetylation of **4b** and **4e** with MeONa/MeOH gave beta-glucuronides **5b** and **5e**. Compound **5e** was converted to beta-glucuronic acid conjugate **6e** by the action of pig liver esterase (PLE). Compound **6e** is a substrate for beta-glucuronidase. Method of a direct introduction of the prodrug residue into MP58 GILGFVFTL (**2b**) failed. Alternately, glycine conjugate **5b** was activated to pentafluorophenyl ester **10**. Model coupling of **10** with Phe-Leu gave tripeptide conjugate ester **11a** which was hydrolyzed by PLE to uronic acid **12**. Condensation of **10** with octapeptide ILGFVFTL (**9**) gave prodrug precursor **11b**. Octapeptide **9** was prepared by de novo synthesis using a racemization-free fragment coupling method. Ester hydrolysis with Ba(OH)₂/MeOH gave the target prodrug **2a** which is a substrate for beta-glucuronidase. Prodrug **2a** does not bind to HLA-A2.1 of T2 human cells defective in major histocompatibility complex I (MHC I) – associated peptide processing. Addition of beta-glucuronidase restored the binding to the level observed with parent nonapeptide **2b** although higher concentrations of prodrug **2a** and enzyme were necessary. This is the first reported synthesis of a prodrug of HLA-A2.1 associated flu peptide.

Task 3 Develop human anti-MP58 CTL line and measure pro-peptide activity with anti-MP58 CTL. Results from this task were described in the 2002 annual report and reported in 2002 Era of Hope meeting. (Appendix C).

MP58 specific human CTL line was established from peripheral blood monocytes of an A2.1 positive normal adult man by repeated stimulation with MP58 loaded antigen presenting cells. Dendritic cells were prepared from blood monocytes by culturing in AIM V medium supplemented with flt3 ligand, c-kit ligand, GM-CSF, TNF-alpha and IL-4 for 6 days in 10% autologous serum (1). Such DC were loaded with 40 ug/ml MP58 peptide in the presence of 3 ug/ml beta-microglobulin for 2 hrs at 37 degree. After three washes, DC were incubated with autologous CD8+ T cells in medium containing 10 ng/ml of IL-7. CD8 T cells were prepared by negative depletion of blood MNC which expressed CD20, CD4, CD14 and CD32, using magnetic beads. The antigenic stimulation was repeated with monocytes as the antigen presenting cells. Over 80% of MP58 loaded T2 cells were lysed by CTL at E:T ratio of 10:1 – 2:1. The same CTL did not lyse T2 cells loaded with pro-peptide beta-Glu-MP58. In the presence of beta-glucuronidase, 80% of T2 cells were lysed, demonstrating liberation of active MP58 from the prodrug to mark tumor cells for CTL lysis. These results demonstrate that immunogenic peptide prodrugs are converted to active peptide by beta-glucuronidase and mark tumor cells for CTL mediated lysis.

Additional study

Peptide or pro-peptide may be too short-lived *in vivo* to be therapeutically effective. To increase pro-peptide stability *in vivo*, lipoprotein conjugates were synthesized using a universal helper epitope PADRE, aK(X)VAAWTLKAAa, as the test peptide. LDL (Sigman) was triple washed with heptane to extract the lipids. Apoprotein B was suspended in PBS by vortexing and aqueous solution of PADRE at 1 mg/ml was added, vortexed and lyophilized at -50 degree for 12 hrs. Lipid extract was added to the powder mixture of apoprotein B and peptide, mixed by vortex. Heptane was slowly removed using rotoevaporator at 40 degree for 30 min under vacuum. When incubated with tumor cells, 55 and 20% of PADRE and PADRE/lipoprotein conjugate, respectively, was degraded in 2 hrs by peptidase on the cell surface. PADRE and lipoprotein conjugated PADRE induced similar lymphoproliferation of T cells. Therefore, it

should be feasible to conjugate pro-peptide drugs to lipoprotein to increase stability while maintaining activity *in vivo*.

KEY RESEARCH ACCOMPLISHMENTS

1. An in vitro 3-D tumor growth inhibition assay was used to demonstrate the feasibility of delivering antigenic peptide to mark a growing solid tumor for CTL destruction (Appendix A).
2. Beta-Glu-MP58, pro-peptide of flu MP-58 GILGFVFTL, was synthesized. In the presence of β -glucuronidase, MP-58 peptide is released from the pro-peptide and bound to HLA-A2.1. (Appendix B).
3. A human CTL line to flu peptide MP58 was established. Anti-MP58 CTL lysed T2 cells loaded with pro-peptide beta-Glu-MP58 only in the presence of beta-glucuronidase, demonstrating liberation of active MP58 from the prodrug to mark tumor cells for CTL lysis. (Appendix C).
4. A lipoprotein conjugate of the universal helper epitope PADRE was synthesized and demonstrated increased in vivo stability.

REPORTABLE OUTCOMES

Wei-Zen Wei, Stuart Ratner, Terry Shibuya, George Yoo and Agnes Jani, Foreign antigenic peptides delivered to the tumor as targets of cytotoxic T cells. *J. Immunol. Method.* 258:141-150, 2001

Rewale, S., Hrihorczuk, LM., Wei, WZ and Zemlicka, J., Synthesis and biological activity of prodrug of class I major histocompatibility peptide GILGFVFTL activated by beta-glucuronidase. *Journal of Medicinal Chemistry.* 45: 937-943, 2002

Wei-Zen Wei, Sharad Rawale, Diego Laderach, *Lew M. Hrihorczuk, and Jiri Zemlicka
Therapeutic prodrug of HLA-A2.1 associated flu peptide MP58 GILGFVFTL activated by β -glucuronidase. *Era of Hope 2002 (Abstract)*

CONCLUSIONS

MP58 pro-peptide has been synthesized and is a candidate immunotherapeutic agent in HLA-A2.1 patients. Functional MP58 peptide can be released by beta-glucuronidase to bind HLA-A2.1 on target cells, marking them for specific CTL lysis. A universal peptide PADRE can be stabilized in lipoprotein conjugate while maintaining CD4 T cell stimulating activity. Prodrugs of immunogenic peptides combined with PADRE are potential therapeutic agents for solid tumors.

PERSONNEL

Wei-Zen Wei, Ph.D. PI
Jiri Zemlicka, PhD. co-investigator
Sharad Vithalraol Rawale, Ph.D. post-doctoral fellow
Jennifer Jacob, Ph.D. post-doctoral fellow
Benjamin Wei, student tech

APPENDICES

- A. Wei-Zen Wei, Stuart Ratner, Terry Shibuya, George Yoo and Agnes Jani, Foreign antigenic peptides delivered to the tumor as targets of cytotoxic T cells. *J. Immunol. Method.* 258:141-150, 2001
- B. Rewale, S., Hrihorczuk, LM., Wei, WZ and Zemlicka, J., Synthesis and biological activity of prodrug of class I major histocompatibility peptide GILGFVFTL activated by beta-glucuronidase. *Journal of Medicinal Chemistry.* 45: 937-943, 2002
- C. Wei-Zen Wei, Sharad Rawale, Diego Laderach, *Lew M. Hrihorczuk, and Jiri Zemlicka, Therapeutic prodrug of HLA-A2.1 associated flu peptide MP58 GILGFVFTL activated by β -glucuronidase. *Era of Hope 2002 (Abstract)*

Reprinted from

JIM

Journal of
Immunological Methods

Journal of Immunological Methods 258 (2001) 141–150

Foreign antigenic peptides delivered to the tumor as targets of cytotoxic T cells

Wei-Zen Wei *, Stuart Ratner, Terry Shibuya, George Yoo, Agnes Jani

Karmanos Cancer Institute, Wayne State University, 110 E. Warren Avenue, Detroit, MI 48201, USA

Received 17 May 2001; received in revised form 3 August 2001; accepted 7 August 2001

Scope of the Journal

The JOURNAL OF IMMUNOLOGICAL METHODS is devoted to covering techniques for: (1) quantitating and detecting antibodies and/or antigens and haptens based on antigen-antibody interactions; (2) fractionating and purifying immunoglobulins, lymphokines and other molecules of the immune system; (3) isolating antigens and other substances important in immunological processes; (4) labelling antigens and antibodies with radioactive and other markers; (5) localizing antigens and/or antibodies in tissues and cells, in vivo or in vitro; (6) detecting, enumerating and fractionating immunocompetent cells; (7) assaying for cellular immunity; (8) detecting cell-surface antigens by cell-cell interactions; (9) initiating immunity and unresponsiveness; (10) transplanting tissues; (11) studying items closely related to immunity such as complement, reticuloendothelial system and others.

In addition the journal will publish articles on novel methods for analysing the organization, structure and expression of genes for immunologically important molecules such as immunoglobulins, T cell receptors and accessory molecules involved in antigen recognition, processing and presentation. Submitted full length manuscripts should describe new methods of broad applicability to immunology and not simply the application of an established method to a particular substance although papers describing such applications may be considered for publication as a short Technical Note.

The Recombinant Technology section will contain articles relating to modification by recombinant techniques of molecules of immunological interest; isolation of novel binding proteins by phage display; gene therapy; transfection; and expression. Immunology Protocols is a section providing detailed, step-by-step descriptions of new and established techniques in immunology. Articles on the molecular biological analysis of immunologically relevant receptor binding sites are also invited.

Editors

M.C. Nussenzweig, *The Rockefeller University, 1230 York Avenue, New York, NY 10021-6399, USA*. E-mail address: nussen@rockvax.rockefeller.edu

M.W. Turner, *Immunobiology Unit, Institute of Child Health, University College London, 30 Guilford Street, London WC1N 1EH, UK*. E-mail address: m.turner@ich.ucl.ac.uk

Recombinant Technology Section Editor

A.J.T. George, *Department of Immunology, Division of Medicine, Imperial College of Medicine, Hammersmith Hospital, London W122 0NN, UK*.

E-mail address: a.george@ic.ac.uk

Immunology Protocols Editor

A.R. Mire-Sluis, *Genentech Inc., BioAnalytical Sciences, Mail Stop 38, 1 DNA Way, South San Francisco, CA 94080-4990, USA*. E-mail address: tms@gene.com

Software Notice Editor

S.J. Merrill, *Department of Mathematics, Statistics and Computer Science, Marquette University, P.O. Box 1881, Milwaukee, WI 53201-1881, USA*. E-mail address: stevem@jim.msccs.mu.edu

Editorial Board

C.R. Alving, *Washington DC, USA*

R.S. Basch, *New York, NY, USA*

L. Bignold, *Adelaide, Australia*

P. Bongrand, *Marseilles, France*

F. Borek (Founding Editor), *Tel Aviv, Israel*

N. Borregaard, *Copenhagen, Denmark*

L.K. Borysiewicz, *Cardiff, UK*

P. Brandtzaeg, *Oslo, Norway*

K.A. Brown, *London, UK*

J. Burnie, *Manchester, UK*

J.D. Capra, *Oklahoma City, OK, USA*

S. Challacombe, *London, UK*

M. Chapman, *Charlottesville, VA, USA*

E. Claassen, *Lelystad, The Netherlands*

N.R. Cooper, *La Jolla, CA, USA*

B. Diamond, *Bronx, NY, USA*

C.A. Dinarello, *Denver, CO, USA*

J. Fabre, *London, UK*

J. Goding, *Parkville, Australia*

J. Greenman, *Hull, UK*

J.-L. Guesdon, *Paris, France*

H. Hoogenboom, *Maastricht, The Netherlands*

C.S. Hosking, *Newcastle, Australia*

P. Hudson, *Parkville, Australia*

J. Huston, *Lexington, MA, USA*

K. James, *Edinburgh, UK*

R. Jefferis, *Birmingham, UK*

J.C. Jensenius, *Århus, Denmark*

A.P. Johnstone, *London, UK*

M. Kazatchkine, *Paris, France*

T. Kinoshita, *Osaka, Japan*

H. Koprowski, *Philadelphia, PA, USA*

J. Laman, *Rotterdam, The Netherlands*

M. Lamm, *Cleveland, OH, USA*

R.G. Leslie, *Odense, Denmark*

R.N. Maini, *London, UK*

J.L. Maryanski, *Epalinges, Switzerland*

L. McPhail, *Winston-Salem, NC, USA*

A. Meagar, *Potters Bar, UK*

M. Melamed, *London, UK*

P. Minor, *Potters Bar, UK*

S.L. Morrison, *Los Angeles, CA, USA*

W.J.W. Morrow, *London, UK*

E. Nardin, *New York, NY, USA*

D.J. Newman, *Carshalton, UK*

J.J. Oppenheim, *Frederick, MD, USA*

M.G. Ormerod, *Reigate, UK*

T. Out, *Amsterdam, The Netherlands*

I. Poxton, *Edinburgh, UK*

E. Pure, *Philadelphia, PA, USA*

K.B.M. Reid, *Oxford, UK*

S.J. Rodda, *Victoria, Australia*

P. Rubinstein, *New York, NY, USA*

J. Sedgwick, *Palo Alto, CA, USA*

A.W. Segal, *London, UK*

E.M. Shevach, *Bethesda, MD, USA*

F. Sinigaglia, *Milan, Italy*

N. Staines, *London, UK*

R. Steinman, *New York, NY, USA*

C.R. Stokes, *Bristol, UK*

D. Stollar, *Boston, MA, USA*

D. Stott, *Glasgow, UK*

R.C. Thorpe, *Potters Bar, UK*

H. Towbin, *Basel, Switzerland*

P.A. Underwood, *North Ryde, Australia*

J.C. Unkeless, *New York, NY, USA*

R. Van Furth, *Oegstgeest, The Netherlands*

M. Van Regenmortel, *Strasbourg, France*

J. Vilcek, *New York, NY, USA*

J.W.M. Visser, *New York, NY, USA*

A. Voller, *Berkhamsted, UK*

J.R. Yannelli, *Lexington, KY, USA*

F. Zavala, *New York, NY, USA*

H. Zola, *Adelaide, Australia*

S.B. Zolla-Pazner, *New York, NY, USA*

Publication information: *Journal of Immunological Methods* (ISSN 0022-1759). For 2001, volumes 248–259 are scheduled for publication. Subscription prices are available upon request from the Publisher or from the Regional Sales Office nearest you or from this journal's website (<http://www.elsevier.nl/locate/jim>). Further information is available on this journal and other Elsevier Science products through Elsevier's website (<http://www.elsevier.nl>). Subscriptions are accepted on a prepaid basis only and are entered on a calendar year basis. Issues are sent by standard mail (surface within Europe, air delivery outside Europe). Priority rates are available upon request. Claims for missing issues should be made within six months of the date of dispatch.

Orders, claims, and product enquiries: please contact the Customer Support Department at the Regional Sales Office nearest you:

New York: Elsevier Science, PO Box 945, New York, NY 10159-0945, USA; phone: (+1) (212) 633 3730, [toll number for North American customers: 1-888-4ES-INFO (437-4636)]; fax: (+1) (212) 633 3680; e-mail: usinfo-f@elsevier.com

Amsterdam: Elsevier Science, P.O. Box 211, 1000 AE Amsterdam, The Netherlands; phone: (+31) 20 485 3757; fax: (+31) 20 485 3432; e-mail: nlinfo-f@elsevier.nl

Tokyo: Elsevier Science K.K., 9-15 Higashi-Azabu 1-chome, Minato-ku, Tokyo 106-0044, Japan; phone: (+81) (3) 5561 5033; fax: (+81) (3) 5561 5047; e-mail: info@elsevier.co.jp

Singapore: Elsevier Science, No. 1 Temasek Avenue, #17-01 Millenia Tower, Singapore 039192; phone: (+65) 434 3727; fax: (+65) 337 2230; e-mail: asiainfo@elsevier.com.sg

Rio de Janeiro: Elsevier Science, Rua Sete de Setembro 111/16 Andar, 20050-002 Centro, Rio de Janeiro – RJ, Brazil, phone: (+55) (21) 509 5340; fax: (+55) (21) 507 1991; e-mail: elsevier@campus.com.br [Note (Latin America): for orders, claims and help desk information, please contact the Regional Sales Office in New York as listed above]

Author enquiries

For enquiries relating to the submission of articles (including electronic submission), the status of accepted articles through our Online Article Status Information System (OASIS), author Frequently Asked Questions and any other enquiries relating to Elsevier Science, please consult <http://www.elsevier.com/locate/authors/>

For specific enquiries on the preparation of electronic artwork, consult <http://www.elsevier.com/locate/authorartwork/>

Contact details for questions arising after acceptance of an article, especially those relating to proofs, are provided when an article is accepted for publication.

Foreign antigenic peptides delivered to the tumor as targets of cytotoxic T cells

Wei-Zen Wei^{*}, Stuart Ratner, Terry Shibuya, George Yoo, Agnes Jani

Karmanos Cancer Institute, Wayne State University, 110 E. Warren Avenue, Detroit, MI 48201, USA

Received 17 May 2001; received in revised form 3 August 2001; accepted 7 August 2001

Abstract

Cytotoxic T cells (CTL) are readily activated by immunogenic peptides and they exert potent anti-tumor activity if the same peptides are displayed on class I major histocompatibility complex (MHC) of the tumor cells. A handful of tumor-associated antigens have been identified and many of them are weak antigens. As an alternative strategy, strongly antigenic foreign peptides are delivered to the tumor, marking them for CTL recognition. To establish the principle of this new strategy, *in vitro* and *in vivo* tumor destruction was tested with BALB/c CTL to L^d-associated beta-galactosidase (β -gal) peptide p876. *In vitro*, anti-p876 CTL destroyed tumor cells in a single-cell suspension or in 3-D tumor boluses when exogenous p876 was added. Exogenous IL-2 was required to sustain CTL activity for complete destruction of tumor boluses. *In vivo*, BALB/c mice were immunized with p876 and a CD4 activating Pan DR reactive epitope (PADRE). PADRE, which binds to several different MHC class II antigen and activates CD4 T cells, induced delayed-type hypersensitivity and stimulated T cell proliferation. Immunized mice were injected with tumor cells loaded with p876 and mixed with PADRE. Starting from the day after tumor injection, mice received five rounds of peptide injection at the tumor sites and all tumors were rejected. Injection with saline had no effect. Injection with PADRE had minor anti-tumor activity. Immunization and treatment with p876 alone was not protective. Therefore, by delivering CD4 and CD8 reactive foreign peptides to the tumor, peptide-specific T cells rejected the tumors as demonstrated by the *in vitro* and *in vivo* tests. © 2001 Elsevier Science B.V. All rights reserved.

Keywords: CTL; Antigenic peptide; Cancer therapy; Prodrug

1. Introduction

Vaccination with tumor-associated, major histocompatibility complex (MHC) class I antigen-re-

stricted immunogenic peptides can induce tumor antigen-specific immunity. BALB/c mammary tumor growth was inhibited in mice immunized with peptide E474 from the envelope protein of mouse mammary tumor virus (MMTV) (Wei et al., 1996a,b). HLA-A1-associated MAGE-3 peptide induced tumor shrinkage in three of sixteen melanoma patients (Marchand et al., 1995). Immunization with HLA-A2-restricted gp100 peptide combined with systemic IL-2 treatment induced partial response in 42% of melanoma patients (Rosenberg et al., 1998). Patients with metastatic melanoma showed complete

Abbreviations: CTL, cytotoxic T cells; MHC, major histocompatibility complex; CFA, complete Freund's adjuvant; MMTV, mouse mammary tumor virus; PADRE, Pan DR reactive epitope; β -Gal, beta-galactosidase.

^{*} Corresponding author. Tel.: +1-313-833-0715x2360; fax: +1-313-831-7518.

E-mail address: weiw@karmanos.org (W.-Z. Wei).

response after they were immunized with dendritic cells loaded with three melanoma peptides (Nestle et al., 1998). These examples indicated the anti-tumor efficacy of peptide-specific cytotoxic T cells (CTL).

Several limitations in tumor-specific immunotherapy prompted us to search for alternative approaches. Antigen expression by tumor cells is heterogeneous and T cells recognizing tumor-specific antigens may eliminate antigen positive tumor cells, but allow the expansion of antigen negative cells. A limited number of tumor-associated antigens have been identified and many of them are weak antigens (Pardoll, 1998). When immunity to tumor-associated self antigens is successfully induced, autoimmunity becomes a risk factor. An alternative approach to exploit effector T cells without being limited by the tumor-associated antigens will be of great advantage.

Chemotherapeutic agents can be delivered to the tumors under the cover of pro-drugs. A nontoxic glucuronyl-spacer-doxorubicin prodrug HMR 1826 was activated selectively by β -glucuronidase which is found at high concentration at the tumor site (Murdter et al., 1997; Bosslet et al., 1998). Treatment with HMR 1826 resulted in tumor destruction without systemic toxicity. The findings with HMR 1826 encouraged the strategy of delivering antigenic peptides under the cover of pro-peptides. A pro-peptide can be synthesized by conjugating glucuronide to the amino terminus through the self-immolative linker (Rawale et al., 2001). The pro-peptide does not bind to MHC class I antigen, but β -glucuronidase can cleave and release the active peptide, which then binds to MHC class I antigen. The current study is undertaken to establish the in vitro and in vivo assay methods for measuring anti-tumor activity of CTL to foreign peptides.

Therapeutic potential of CTL against a solid tumor was first demonstrated in vitro in collagen gel (Wei et al., 1985, 1996a,b). Tumor cells grew as a 3-D mass with intracellular junctions and resembled a solid tumor. The tumor mass could be maintained in the collagen gel for 1–2 weeks, providing prolonged observation period and a realistic in vitro system to measure anti-tumor activity (Gavin et al., 1993). Activated T cells migrated through the collagen gel (Ratner et al., 1992) and inhibition of tumor growth was monitored by daily measurement of the tumor size.

To sustain CTL activity in vivo, CD4 T cells were activated by Pan DR reactive epitope (PADRE) aK(X)VAAWTLKAAa (a is D-alanine and X is cyclohexylalanine), a synthetic peptide containing amino acid sequences derived from the circumsporozoite protein (CSP) from *Plasmodium falciparum*. PADRE binds multiple LHA-DR allospecificity and murine I-A^{b/d} or I-E^{b/d} antigens (Alexander et al., 1994) and induces helper T cell activity. The efficacy of PADRE to enhance anti-tumor CTL activity was examined.

2. Materials and methods

2.1. Mice and cell lines

BALB/c mice originally obtained from the Cancer Research Laboratory, Berkeley, CA were bred by brother–sister mating in our animal care facility. The use and care of experimental mice are in accordance with the guidelines of Wayne State University Animal Investigation Committee. Mouse mammary tumor cell line D2F2 was cloned from a spontaneous mammary tumor, which arose in a BALB/c hyperplastic alveolar nodule line D2 (Mahoney et al., 1985). MMT cell line 168 was cloned from a spontaneous tumor in a BALB/cfC3H mouse which was the offspring of BALB/c mice foster nursed on C3H/HeJ mothers infected with MMTV(C3H) (Wei et al., 1993). Cell line 293 (American Type Culture Collection, Manassas, VA) is a human embryonic kidney cell line transformed with Ad5 E1A and E1B genes, and supports the propagation of E1 deleted recombinant adenovirus. All tissue culture reagents were obtained from GIBCO Laboratories (Grand Island, NY) unless otherwise specified. The cell lines were maintained in Dulbecco's modified Eagle's medium (DME) supplemented with 5% heat-inactivated fetal calf serum (HyClone, Logan, UT), 10% NCTC 109 medium (Sigma, St. Louis, MO), 8 μ g/ml bovine crystalline insulin (Sigma), 1 mM oxalacetic acid, 0.5 mM sodium pyruvate, 2 mM L-glutamate, 0.1 mM MEM nonessential amino acids, 100 units/ml penicillin and 100 μ g/ml streptomycin.

2.2. Peptides

Beta-galactosidase (β -gal) peptide p876 TPH-PARIGL and PADRE aK(X)VAAWTLKAAa (a is D-alanine and X is cyclohexylalanine) were synthesized at Genemed Synthesis (South San Francisco, CA).

2.3. Establishment of peptide-specific CTL

BALB/c mice were injected s.c. at the tail base with 100 μ g of p876 emulsified in 0.1 ml of 50% complete Freund's adjuvant (CFA). At 10 days after the injection, the spleen and lymph nodes were aseptically removed from immunized mice and a single-cell suspension was prepared. The freshly isolated cells were cultured with peptide-loaded, irradiated splenocytes in 12-well plates in RPMI 1640 medium containing 50 μ M of 2-mercaptoethanol, 10% fetal calf serum, 5% mixed leukocyte culture supernatant and 18 IU/ml of recombinant hIL-2 (Cetus, Emeryville, CA). The ratio of stimulators to responders was 2:1.

To prepare the stimulators, autologous splenocytes were incubated with 100 μ g/ml of p876 for 2 h, exposed to 1000 rad irradiation from a Cesium irradiator and washed to remove excess peptides before they were added to the culture. The cultured cells were re-stimulated with peptide-loaded splenocytes every 7–10 days.

Mixed leukocyte culture was prepared by incubating BALB/c splenocytes with irradiated human peripheral blood leukocytes for 48 h in RPMI 1640 medium with 10% FCS. The ratio of mouse and human cells was 1:1 and the total cell concentration was 5×10^6 cells/ml.

2.4. ^{51}Cr release assay

D2F2 tumor target cells were labeled by incubating 10×10^6 cells with 100 μ Ci $\text{Na}^{51}\text{CrO}_4$ (NEN Research Products, Boston, MA) in 1 ml of complete DME at 37 °C for 2 h. In some experiments, the target cells were loaded with p876 peptide by adding 100 μ g of p876 during the incubation. The unincorporated ^{51}Cr and unbound peptide was removed by three washes with Hanks' balanced salt solution containing 2% calf serum and 2 mM Hepes buffer.

Graded numbers of effector cells were mixed with 1×10^5 labeled target cells in 200 μ l of DME in the wells of round bottom microtiter plates. After centrifugation at $200 \times g$ for 1 min, the plate was incubated at 37 °C for 4.5 h. After the incubation, the plate was centrifuged at $480 \times g$ for 10 min and a 100- μ l aliquot was removed from each well for counting in the gamma counter. The percent lysis was calculated as follows

$$\% \text{ specific lysis} = 100 \times (\text{cpm}_{\text{test}} - \text{cpm}_{\text{medium}}) / (\text{cpm}_{\text{max}} - \text{cpm}_{\text{medium}}).$$

The cpm_{max} was determined by adding 1/6 N HCL to wells containing ^{51}Cr -labeled target cells. Each group contained four replicates.

2.5. A 3-D collagen gel assay

The growth and lysis of tumor cell boluses in the collagen were previously reported (Wei et al., 1996a,b) and are briefly described here. Collagen stock solution was prepared from rat tail tendons. The complete collagen mixture contained 12 parts of cold collagen stock, 2 parts of $7.5 \times \text{RPMI 1640 medium}$, 0.6 parts of 7.5% sodium bicarbonate and 0.5 parts of 0.34 N NaOH. This mixture stayed in liquid form if kept on ice. Tumor cell boluses were prepared by suspending 1×10^5 tumor cells with or without CTL in 1 μ l of complete collagen mixture and embedded between two layers of collagen gels. The gel was bathed in RPMI 1640 medium supplemented with 50 μ M of 2-mercaptoethanol, 10% fetal calf serum, 5% mixed leukocyte culture supernatant and 18 IU/ml of recombinant hIL-2 (Cetus). Tumor cells established inter-cellular junction and formed a cell mass during overnight culture (Wei et al., 1985, 1996a,b). In some experiments, the CTL were added to the top of the collagen and allowed to migrate into the gel. Peptide p876 was added the day after CTL were embedded or added. The plates were incubated at 37 °C and tumor growth was measured every other day.

Tumor cell boluses embedded in collagen gel were examined with an inverted microscope equipped with a split image tracing device, using $1 \times$ objective. The projected image of the cell bolus

was traced and the surface area was calculated. The result was expressed as the square root of the measured area, which represented the mean diameter of the bolus, multiplied by a constant. The difference between the test and control group was determined with one-tail Student's *t*-test. There were four replicates in each group.

2.6. Foot pad swelling test

BALB/c female mice were immunized by s.c. injection with 20 µg of PADRE and 100 µg of p876 in 50% IFA, and challenged 2 weeks later in the foot pads with either or both peptides in 20 µl of saline. The thickness of the feet was measured with a caliper at 24 and 48 h after injection. The significance of the swelling was determined by comparing each test group with the saline control group using Student's *t*-test. There were seven to eight mice in each group.

2.7. Lymphocyte proliferation assay

Lymph nodes were removed aseptically from mice, and a single-cell suspension was prepared in RPMI 1640 medium supplemented with 4% fetal calf serum. Suspended cells were distributed to round bottom wells of a 96-well plate and each well received 1.5×10^5 cells. Test peptide at varying concentrations or Concanavalin A (con A) at 1 µg/ml was added to each well. There were four replicates in each group. Cells were incubated in 5% CO₂ at 37 °C for 4 days. Each well received 1 µCi of ³H-thymidine, and the cells were further incubated for 4 h before they were harvested with Harvester96 (Tomtec, Hamden, CT), and the incorporated ³H was counted with TRILUX liquid scintillation and luminescence counter (Wallac, Turku, Finland).

2.8. Preparation of AdCMVLacZ

The construction of AdCMVLacZ was previously reported (Acsadi et al., 1994). The recombinant virus was purified through two rounds of plaque purification, propagated in 293 cells, and isolated on a discontinuous cesium chloride gradient. The virus was collected and the salt was removed with a Se-

phadex column. The quantity of viral particles was estimated by measuring the optical density at 260 nm and the plaque-forming unit (PFU) was determined by direct plaque assay with 293 cells.

2.9. Tumor growth inhibition assay

Female BALB/c mice at 6 weeks of age were immunized by intracutaneous injection with 0.1 ml of saline containing 1×10^{10} PFU of AdCMVLacZ, and boosted, 2 weeks later, by s.c. injection at the tail base with 0.1 ml of 50% IFA containing 100 µg of p876 and/or 20 µg of PADRE. At 2 weeks after vaccination, mice were injected s.c. on the flank with 1×10^5 untreated or peptide-coated D2F2 cells. Starting the day after tumor cell challenge, mice received subcutaneously, every other day, at the tumor site, 0.1 ml of saline containing 100 µg of p876 and/or 40 µg PADRE. A total of five injections were administered and tumor growth was monitored weekly. There were eight mice in each group.

3. Results

3.1. Inhibition of tumor growth by p876-specific CTL *in vitro*

BALB/c CTL to β-gal peptide p876 was established as described in Materials and methods. After the fifth *in vitro* stimulation, more than 99% of the cells were CD8+ (not shown). CTL were frozen between the seventh and tenth stimulation and they were readily reactivated. The specificity was measured by the ⁵¹Cr release assay. CTL lysed peptide p876-coated BALB/c mouse mammary tumor D2F2 cells, but not untreated D2F2 cells (Fig. 1). Expression of L^d by D2F2 cells was verified by flow cytometry (not shown).

The activity of p876-specific CTL against a solid tumor was tested in a 3-D collagen gel to access peptide loading and CTL lysis of a tumor mass. A total of 1×10^5 D2F2 cells and 3×10^5 CTL were embedded together in 1 µl of collagen (Fig. 1B). After an overnight incubation when the cell bolus was established, p876 at 5 or 20 µg/ml was added to the culture and tumor growth was monitored for 7




Fig. 1. Anti-tumor activity of anti-p876 CTL. (A) Cytotoxic activity of anti-p876 CTL measured by the ^{51}Cr release assay. The D2F2 cells were labeled with $\text{Na}^{51}\text{CrO}_4$ in the presence (solid circle) or absence (open triangle) of p876 and chromium release was measured after a 4.5-h incubation at 37°C with anti-p876 CTL. There were four replicates in each group. (B–D) Inhibition of D2F2 tumor growth by anti-p876 CTL in 3-D collagen gel. (B) A total of 1×10^5 D2F2 cells were co-embedded with 3×10^5 anti-p876 CTL in $1 \mu\text{l}$ of collagen. After an overnight incubation at 37°C , p876 at 5 (solid square) or 20 (open triangle) $\mu\text{g}/\text{ml}$ was added to the culture. Control group (solid circle) did not receive peptide. Alternatively, 1×10^5 D2F2 (C) or 168 (D) cells were embedded alone in $1 \mu\text{l}$ of collagen, and 3×10^5 anti-p876 CTL were added to the collagen gel after a tumor mass is established overnight. CTL migrated through the gel and p876 peptide was added after 24 h. Tumor growth was measured by the square root of the growth area. * indicates significant difference between the control and test groups at $P < 0.005$.

days. Without exogenous p876, D2F2 cells, co-embedded with anti-p876 CTL, grew progressively. The addition of p876 resulted in profound inhibition of tumor growth. Therefore, tumor cells in the solid mass were loaded with the exogenous peptide and are targets of CTL lysis.

Anti-tumor activity was further tested by embedding D2F2 cells in the collagen to establish a tumor mass before CTL and peptides were added. Therefore, 1×10^5 D2F2 cells were embedded and incu-

bated overnight to establish a tumor mass with intercellular junctions (Miller et al., 1985) (Fig. 1C). CTL were added to the top of the gel and approximately 20–40% of CTL migrated through the collagen in 18 h (Ratner et al., 1992) when peptide p876 at 5 or 20 $\mu\text{g}/\text{ml}$ was added. Complete disintegration of the tumor boluses was observed after 5 days of culture. Vigorous proliferation of CTL was observed in and around the tumor (not shown). The destruction of tumor cell boluses was verified with another mouse




Fig. 2. D2F2 tumor growth in p876-immunized and treated mice. BALB/c mice were immunized i.c. with 1×10^{10} PFU of *AdCMVLacZ* and boosted with β -gal p876. At 2 weeks after vaccination, each mouse received s.c., 1×10^5 D2F2 cells coated or not-coated with β -gal p876. Mice injected with peptide-coated cells received peri-lesional injection of 200 μ g p876 in 100 μ l of saline every other day, five times, starting the day after tumor cell injection. Control mice received saline injection or were not treated.

mammary tumor cell line 168, which also expressed L^d antigen (Fig. 1D). The extended culture period of the tumor boluses will be a particular advantage for testing pro-peptides, which are released by tumor-associated enzymes.

3.2. Effect of p876 on tumor growth in BALB/c mice

To test anti-tumor activity of p876-specific CTL in vivo, BALB/c mice were immunized with *AdCMVLacZ* to activate β -gal specific CTL and boosted in 2 weeks with 100 μ g p876 in IFA. At 2 weeks after peptide immunization, mice were challenged with D2F2 cells pre-coated with p876. Starting the day after tumor cell challenge, mice were injected at the tumor site, every other day, with 200 μ g of p876 in 0.1 ml saline. There were five injections in 10

days. Control mice received saline or were not treated. One group received uncoated D2F2 cells. There was no demonstrable protection in any of the treatment group (Fig. 2). We previously showed that immunization with irrelevant peptides had no effect on tumor growth (Wei et al., 1996a,b). The inability to inhibit tumor growth by local administration of p876 may be due to inadequate number of CTL at the tumor site as a result of inadequate cytokine or accessory signals. In the 3-D collagen, exogenous IL-2 was required to achieve complete tumor destruction, indicating that continued stimulation and expansion of the CTL was necessary for controlling tumor growth (Wei et al., 1996a,b).

3.3. T cell activation by PADRE

To enhance local recruitment or maintenance of CTL, CD4 T cell reactive peptide was incorporated

Table 1
Delayed-type hypersensitivity induced by PADRE

Vaccination	Challenge	Change in foot pad thickness (mm)			
		Day 1	P value	Day 2	P value*
PADRE/IFA ^a	PADRE	57.4 \pm 22.0	< 0.0002	36.1 \pm 19.3	< 0.002
IFA	PADRE	13.4 \pm 19.3	> 0.05	14.0 \pm 13.9	> 0.05
PADRE/IFA	Saline	2.9 \pm 7.4	> 0.05	6.0 \pm 18.4	> 0.05
IFA	Saline	6.6 \pm 16.0	> 0.05	3.6 \pm 6.6	> 0.05

^a Mice were immunized and challenged as described in Materials and methods. There were eight mice in each group.

* P value was determined by the Student's *t*-test.

Table 2
Delayed-type hypersensitivity induced by PADRE and β -gal

Challenge	Change in foot pad thickness (mm)			
	Day 1	<i>P</i> value	Day 2	<i>P</i> value*
PADRE	38.6 \pm 6.6	< 0.001	24.3 \pm 8.6	< 0.01
β -gal/ PADRE	49.3 \pm 25.4	< 0.05	39.4 \pm 18.4	< 0.0005
β -gal	12.1 \pm 14.7	> 0.05	8.7 \pm 14.7	> 0.05
Saline	3.9 \pm 7.1		5.3 \pm 9.6	

Mice were immunized and challenged as described in Materials and methods. There were eight mice in each group.

* *P* value was determined by the Student's *t*-test.

into the treatment regimen. PADRE, which binds to a wide range of human and murine MHC class II antigen, was tested as local CD4 T cell activator. The immunogenicity of PADRE was tested by the foot pad swelling assay. BALB/c mice were immunized s.c. with 20 μ g of PADRE in 0.1 ml of 50% CFA and challenged 2 weeks later in the foot pad with 40 μ g of PADRE in 20 μ l of saline. Significant swelling was induced by PADRE both 1 and 2 days after challenge (Table 1). Injection of PADRE in control mice or injection of saline in PADRE-immunized mice did not induce significant swelling. Therefore, PADRE-specific T cells were activated in vivo by peptide immunization. Delayed-type hypersensitivity, induced by a combination of p876 and PADRE, was also tested. Mice were immunized with 100 μ g of p876 and 20 μ g of PADRE in Incomplete Freund's adjuvant and challenged 2 weeks later with p876, PADRE or a mixture of both peptides. Significant increase in foot pad thickness was observed

after PADRE was injected (Table 2). Injection of both p876 and PADRE further enhanced the immune reactivity. p876 alone did not have significant effect. These results support the immunogenicity of PADRE in BALB/c mice and an enhanced inflammatory reaction when both MHC class I and II antigen reactive peptides were present.

Activation of T cells was also measured by lymphocyte proliferation assay (Table 3). Lymph node cells were prepared from BALB/c mice 2 weeks after mice were immunized s.c. with 20 μ g of PADRE in 0.1 ml of 50% CFA. Immune cells were incubated with 0.1–10 μ g of PADRE and 3 H-thymidine incorporation was measured after 4 days of culture. Incorporation of 3 H-thymidine was increased by more than 100 fold in sensitized lymphocytes when incubated with 10 μ g of PADRE. Naïve lymphocytes did not demonstrate significant activity, supporting specific immune activation by PADRE.

3.4. Anti-tumor activity of p876 and PADRE

To test the therapeutic effect of p876 and PADRE, BALB/c mice were immunized with AdCMVLacZ and boosted in 2 weeks with 100 μ g p876 and 20 μ g PADRE in IFA. At 2 weeks after the second immunization, mice received s.c. D2F2 cells pre-coated with p876 and mixed with PADRE. Mice were treated five times at the tumor site with a mixture of PADRE and p876, every other day. Complete inhibition of D2F2 tumor growth was observed in mice treated with PADRE and p876 (Fig. 3). Immunization and treatment with PADRE alone had a minor anti-tumor activity (not shown). These re-

Table 3
Lymphocyte proliferation induced by PADRE

Treatment ^a	Mean \pm S.D. (cpm)			
	Immune	<i>P</i> value	Normal	<i>P</i> value*
Medium	145 \pm 141		47 \pm 14	
PADRE 0.1 μ g/ml	269 \pm 136	> 0.05	40 \pm 10	> 0.05
PADRE 5 μ g/ml	6360 \pm 974	< 0.005	183 \pm 117	> 0.05
PADRE 10 μ g/ml	18 167 \pm 3784	< 0.005	137 \pm 158	> 0.05
Con A 1 μ g/ml	92 765 \pm 11 148	< 0.005	78 263 \pm 16 138	< 0.005

^a Lymph node cells were pooled from three mice 2 weeks after PADRE immunization and stimulated with PADRE as described in Materials and methods.

* *P* value was determined by the Student's *t*-test.




Fig. 3. Inhibition of D2F2 tumor growth by PADRE and p876. BALB/c mice were immunized i.c. with 1×10^{10} PFU of *AdCMVLacZ* and boosted 2 weeks later by s.c. injection with 100 μ g of p876 and 20 μ g of PADRE in 50% IFA. At 2 weeks after vaccination, each mouse received s.c. 1×10^5 D2F2 cells (A) or D2F2 cells coated with β -gal p876 and mixed with PADRE (B–D). Mice in group (C) received a peri-lesional injection with p876 (200 μ g) and PADRE (40 μ g) in 100 μ l of saline every other day, five times, starting from the day after tumor cell injection. Control mice were not treated (B) or received saline injections (D). The lower panel showed the average tumor diameter in groups A–D.

sults demonstrated that activation of both CD4 and CD8 T cells at the tumor site with foreign peptide eliminated tumors loaded with the specific peptides.

4. Discussion

This study outlines a scheme for inducing and measuring anti-tumor activity mediated by T cells to foreign peptides. CTL to β -gal peptide p876 eliminated tumor boluses in a 3-D matrix, demonstrating

effective loading of p876 in a solid mass, migration of CTL to the tumor and sustained CTL killing at the tumor site. Exogenous IL-2 was necessary to maintain CTL activity. In vivo, tumors were rejected if they were loaded with p876 and PADRE and treated locally with the same peptides. PADRE was required to sustain CTL activity in vivo. Although tumor cells were loaded with peptides in this study, it should be possible to deliver foreign peptides onto tumor cells in vivo by appropriate vehicles. The pro-peptide developed by our group does not bind MHC class I

antigen until the active peptide is released by beta-glucuronidase (Rawale et al., 2001 ID: 2226). Based on the same principle, doxorubicin prodrug HMR 1826 was activated selectively at the tumor site by β -glucuronidase and demonstrated anti-tumor activity without systemic toxicity (Murdter et al., 1997; Bosslet et al., 1998). It is anticipated that pro-peptide can be delivered to the tumors by systemic administration. The 3-D tumor growth assay and in vivo tumor inhibition in the presence of PADRE will be useful for testing pro-peptides and other derivatives of MHC class I antigen-associated peptides.

β -gal encoded by *Escherichia coli lacZ* gene is widely used as a genetic tracer. It is immunogenic and L^d-restricted epitope p876 TPHPARIGL was previously defined (Rammensee et al., 1989; Gavin et al., 1993). Immunization of BALB/c mice with p876 inhibited the growth of a colon carcinoma genetically engineered to express β -gal, supporting the cytotoxic activity of anti- β -gal CTL (Specht et al., 1997). Here, we showed that p876 effectively marked a solid tumor when loaded exogenously onto the tumor cells.

Tumor growth in the 3-D collagen gel is a useful indicator of CTL activity against solid tumors. When CTL were co-embedded with the tumor cells, tumor growth was inhibited, but some tumor cells remained after 2 weeks (not shown). When the same number of CTL were added exogenously, less than half migrated through the gel. These migratory T cells caused complete disintegration of the tumor. When CTL were packed in close proximity in the cell bolus, they may recognize neighboring CTL loaded with p876 and lyse each other. Alternatively, tumor cells may demonstrate immune suppressive activity, e.g. Fas ligand on tumor cells may induce T cell apoptosis. (Whiteside and Rabinowich, 1998; Sarma et al., 1992; Zeytun et al., 1997). These mechanisms can significantly reduce the number of functional effectors in the tumor mass. T cells present in human tumors may be similarly ineffective because of the hostile microenvironment. When the hosts are immunized with foreign peptides, peptide-specific T cells will reside in the peripheral lymphoid organs until they are recruited to the tumor site by the injected peptides. When recruited to the tumor from the periphery, they may be more efficacious than resident T cells against tumor cells.

The in vivo therapeutic effect was striking when both CD4 and CD8 reactive peptides were delivered to the tumor and all tumors were rejected. Delivery of p876 alone was not effective, indicating the need to recruit and sustain CTL activity in vivo. Treatment with PADRE alone had a minor anti-tumor effect (not shown), but was not nearly as effective as p876 and PADRE together. PADRE can bind to I-A^d or I-E^d antigen expressed by the professional antigen presenting cells (APC) or non-professional APC like the endothelial cells (Rose, 1997) and activate CD4 T cells. Interaction between activated CD4 T cells and APC can further enhance the antigen presenting capacity of the latter (Bennett et al., 1998; Schoenberger et al., 1998). Cytokines generated by activated CD4 T cells recruit and activate additional APC, CD8 T cells and non-specific inflammatory cells.

With the proposed scheme, several major obstacles in tumor immunotherapy, namely, tolerance to self-antigens, induction of autoimmunity or the lack of tumor-specific antigens may be circumvented. Because the peptide is foreign, tolerance to the antigen is not an issue. After the peptide treatment is terminated, there is no lingering immune reactivity to self-antigens. Importantly, this therapy does not rely on the expression of tumor-specific antigens because the therapeutic peptides are administered exogenously. Several peptides can be administered simultaneously or sequentially to enhance the therapeutic effect. Each round of peptide treatment represents a booster shot and can increase the frequency of reactive T cells. The observation that 1-day tumor can be eliminated by local delivery of foreign peptides suggests that this strategy may be useful as an adjuvant therapy to eliminate residual tumors at the surgical sites or small tumors not accessible by surgery.

In summary, excellent therapeutic effect was achieved by local delivery of foreign peptides to the tumors. This demonstration provides the basis for developing new strategies to deliver therapeutic foreign peptides to the tumor.

Acknowledgements

The authors wish to thank Ms. Darcy Lichlyter and Serene Lane for their technical assistance. This

study was supported by NIH RO1 CA76340 and USAMRMC (DAMD17-99-1-9244).

References

- Acsadi, G., Jani, A., Massie, B., 1994. A differential efficiency of adenovirus-mediated in vivo gene transfer into skeletal muscle cells of different maturity. *Hum. Mol. Genet.* 3, 579.
- Alexander, J., Sidney, J., Southwood, S., Ruppert, J., Oseroff, C., Macwal, A., Snoke, K., Serra, H.M., Kubo, R.T., Sette, A., Grey, H.M., 1994. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. *Immunity* 1, 751.
- Bennett, S., Carbone, F.R., Karamalis, F., Flavell, R.A., Miller, J.F.A.P., Heath, W.R., 1998. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. *Nature* 393, 478.
- Bosslet, K., Straub, R., Blumrich, M., Czech, J., Gerken, M., Sperker, B., Kroemer, H.K., Gesson, J.P., Koch, M., Monneret, C., 1998. Elucidation of the mechanism enabling tumor selective prodrug monotherapy. *Cancer Res.* 58.
- Gavin, M.A., Gilbert, M.J., Riddell, S.R., Greenberg, P.D., Bevan, M.J., 1993. Alkali hydrolysis of recombinant proteins allows for the rapid identification of class I MHC-restricted CTL epitopes. *J. Immunol.* 151, 3971.
- Mahoney, K.H., Miller, B.E., Heppner, G.H., 1985. FACS quantitation of leucine aminopeptidase and acid phosphatase on tumor associated macrophages from metastatic and non-metastatic mouse mammary tumors. *J. Leukocyte Biol.* 38, 573.
- Marchand, M., Weynants, P., Rankin, E., Arienti, F., Belli, F., Parmiani, G., Cascinelli, N., Boursion, A., Vanwijck, R., Humblet, Y., Canon, J.L., Laurent, C., Naeyaert, J.M., Plagne, R., Deraemaeker, R., Knuth, A., Jager, E., Brasseur, F., Herman, J., Coulic, P.G., Boon, T., 1995. Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. *Int. J. Cancer* 63, 883.
- Miller, B.E., Miller, F.R., Heppner, G., 1985. Factors affecting growth and drug sensitivity of mouse mammary tumor lines in collagen gel cultures. *Cancer Res.* 45, 4200.
- Murder, T.E., Sperker, B., Kivisto, K.T., McClellan, M., Fritz, P., Friedel, G., Linder, A., Bosslet, K., Toomes, H., Dierkesmann, R., Kroemer, H.K., 1997. Enhanced uptake of doxorubicin into a bronchial carcinoma: beta-glucuronidase mediates release of doxorubicin from a glucuronide prodrug (HMR 1826) at the tumor site. *Cancer Res.* 57, 2440.
- Nestle, F.O., Aljagic, S., Gilliet, M., Sun, Y., Grabbe, S., Dummer, R., Burg, G., Schadendorf, D., 1998. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. *Nat. Med.* 4, 328.
- Pardoll, D.M., 1998. Cancer vaccines. *Nat. Med. Vaccine (Suppl. 4)*, 525.
- Rammensee, H.G., Schild, H., Theopold, U., 1989. Protein-specific cytotoxic T lymphocytes. Recognition of transfectants expressing intracellular, membrane-associated or secreted forms of beta-galactosidase. *Immunogenetics* 30, 296.
- Ratner, S., Patrick, P., Bora, G., 1992. Lymphocyte development of adherence and motility in extracellular matrix during IL-2 stimulation. *J. Immunol.* 149, 681.
- Rawale, S.V., Hryhorczuk, L., Wei, W.Z., Zemlicka, J., 2001. Synthesis and preliminary biological studies of T-cell antigenic peptide prodrug activated by beta-glucuronidase. 222nd American Chemical Society National Meeting, Chicago, IL, United States, 2001. American Chemical Society, Washington, D.C.
- Rose, M.L., 1997. Role of endothelial cells in allograft rejection. *Vasc. Med.* 2, 105.
- Rosenberg, S.A., Yang, J.C., Schwartzentruber, D.J., Hwu, P., Marincola, F.M., Topalian, S.L., Restifo, N.P., Dudley, M.E., 1998. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. *Nat. Med.* 4, 321.
- Sarma, V., Wolfe, F.W., Marks, R.M., Shows, T.B., Dixit, V.M., 1992. Cloning of a novel tumor necrosis factor-alpha-inducible primary response gene that is differentially expressed in development and capillary tube-like formation in vitro. *J. Immunol.* 148, 3302.
- Schoenberger, S.P., Toes, R., Van der Voort, E.I.H., Offringa, R., Melief, C.J., 1998. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. *Nature* 393, 480.
- Specht, J.M., Wang, G., Do, M.T., Lam, J.S., Royal, R.E., Reeves, M.E., Rosenberg, S.A., Hwu, P., 1997. Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases. *J. Exp. Med.* 186, 1213.
- Wei, W.Z., Massey, R.J., Heppner, G.H., 1985. A 3-dimensional tumor growth inhibition assay for testing monoclonal antibody cytotoxicity. *Cancer Immunol. Immunother.* 20, 137.
- Wei, W.Z., Gill, R.F., Wang, H., 1993. Mouse mammary tumor virus associated antigens and superantigens-immuno-molecular correlates of neoplastic progression. *Semin. Cancer Biol.* 4, 205.
- Wei, W.Z., Gill, R.F., Jones, R.F., Lichlyter, D., Abastado, J.P., 1996a. Induction of cytotoxic T lymphocytes to murine mammary tumor cells with a Kd-restricted immunogenic peptide. *Int. J. Cancer* 66, 659.
- Wei, W.Z., Miller, B., Gutierrez, R.F., 1996b. Inhibition of tumor growth by peptide specific cytotoxic T lymphocytes in a 3-dimensional collagen matrix. *J. Immunol. Methods* 200, 47.
- Whiteside, T.L., Rabinowich, H., 1998. The role of Fas/FasL in immunosuppression induced by human tumors. *Cancer Immunol. Immunother.* 46, 175.
- Zeytun, A., Hassuneh, M., Nagarkatti, M., Nagarkatti, P.S., 1997. Fas-Fas ligand-based interactions between tumor cells and tumor-specific cytotoxic T lymphocytes: a lethal two-way street. *Blood* 90, 1952.

**Synthesis and Biological Activity of the
Prodrug of Class I Major
Histocompatibility Peptide GILGFVFTL
Activated by β -Glucuronidase**

**Sharad Rawale, Lew M. Hrihorczuk, Wei-Zen Wei, and
Jiri Zemlicka**

Barbara Ann Karmanos Cancer Institute, Wayne State University
School of Medicine, Detroit, Michigan 48201-1379, and Central
Instrumentation Facility, Department of Chemistry, Wayne State
University, Detroit, Michigan 48202

JOURNAL OF
**MEDICINAL
CHEMISTRY®**

Reprinted from
Volume 45, Number 4, Pages 937-943

Synthesis and Biological Activity of the Prodrug of Class I Major Histocompatibility Peptide GILGFVFTL Activated by β -Glucuronidase¹

Sharad Rawale,[†] Lew M. Hrihorczuk,[‡] Wei-Zen Wei,[†] and Jiri Zemlicka^{*,†}

Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan 48201-1379, and Central Instrumentation Facility, Department of Chemistry, Wayne State University, Detroit, Michigan 48202

Received July 30, 2001

The first synthesis of a prodrug of HLA-A2.1 associated antigenic influenza peptide **2a** was accomplished. Two methods for synthesis of prodrugs of antigenic peptides activated by β -glucuronidase and comprising a self-immolative 3-nitrobenzyloxycarbonyl moiety were investigated. Reaction of β -glucuronic acid glycoside of 4-hydroxy-3-nitrobenzyl alcohol (**3**) with *N,N'*-disuccinimidyl carbonate (DSC) followed by conjugation with AlaOMe, Gly, Thr, Phe-Leu, and Leu-Arg gave carbamates **4a–4f**. Deacetylation of **4b** and **4e** with MeONa/MeOH gave β -glucuronides **5b** and **5e**. Compound **5e** was converted to β -glucuronic acid conjugate **6e** by the action of pig liver esterase (PLE). Compound **6e** is a substrate for β -glucuronidase. Method of a direct introduction of the prodrug residue into antigenic nonapeptide GILGFVFTL (**2b**) failed. Alternately, glycine conjugate **5b** was activated to pentafluorophenyl ester **10**. Model coupling of **10** with Phe-Leu gave tripeptide conjugate ester **11a** which was hydrolyzed by PLE to uronic acid **12**. Condensation of **10** with octapeptide ILGFVFTL (**9**) gave prodrug precursor **11b**. Octapeptide **9** was prepared by de novo synthesis using a racemization-free fragment coupling method. Ester hydrolysis with Ba(OH)₂/MeOH gave the target prodrug **2a** which is a substrate for β -glucuronidase. Prodrug **2a** does not bind to HLA-A2.1 of T2 human cells defective in major histocompatibility complex I (MHC I)-associated peptide processing. Addition of β -glucuronidase restored the binding to the level observed with parent nonapeptide **2b** although higher concentrations of prodrug **2a** and enzyme were necessary.

In an effort to design more effective and less toxic drugs against cancer, attention has turned in recent years to prodrugs of antitumor agents. Most of these approaches rely on specific enzymes capable of converting the prodrugs into active species at a tumor site. Selective drug release should reduce the side effects associated with other forms of chemotherapy. This is also the principle of antibody- and gene-directed prodrug therapy (ADEPT^{2,3} and GDEPT⁴). Prodrugs comprising a carbohydrate moiety amenable to enzyme action attached through a self-immolative benzyloxycarbonyl linker to an anticancer drug (e.g., doxorubicin or daunorubicin, compounds **1a–1c**, Chart 1) have attracted a considerable interest.^{5–9} The prodrug-activating enzymes include β -glucuronidase and α - or β -galactosidase. Prodrug **1b** (R₂ = NO₂, HMR 1826) activated by β -glucuronidase liberated in necrotic tumors¹⁰ has an increased efficacy and reduced toxicity relative to that of the parent drug.¹¹ It is a promising candidate for clinical studies.¹²

We have reasoned that this prodrug concept can be extended to antigenic oligopeptides¹³ (8–10 a.a.) which bind to an extracellular domain of class I major histocompatibility complex (MHC I) or human leukocyte antigen (HLA) and are recognized by CD8 positive cytotoxic T lymphocytes (CTL). Interaction between T

cell receptor (TCR) and class I HLA/peptide complex on the target cells triggers CTL activity which mediates target cell lysis.¹⁴ The HLA I peptides on tumor cells originate from endogenous proteins but they can be replaced exogenously by synthetic peptides. It has been shown that CTL can kill tumor cells very effectively if the latter were loaded with appropriate peptides.¹⁵ Thus, mice immunized with tumor-associated peptides rejected tumors expressing the specific peptides.

We can then assume that tumors can be rejected if any antigenic peptide which binds to the appropriate MHC is delivered to the tumor in an immunized host. Systemic delivery of such antigenic peptide is not possible because it will bind to all nucleated cells resulting in severe toxicity. Effective antitumor activity may be achieved if the peptide is converted to a suitable prodrug which will release the peptide only at the tumor site. Glucuronic acid linked through a benzyloxycarbonyl spacer to the N-terminus of the antigenic peptide seems to fulfill such requirements. The anchor residues at or near the N- and C-termini of peptides are necessary for effective interaction¹⁶ with HLA or MHC I. Blocking one of these sites by a bulky prodrug grouping should eliminate or diminish such a binding. As indicated above for prodrugs **1a–c**, β -glucuronidase in the microenvironment of tumors can effectively generate an active drug. Substitution at the N-terminus should also reduce the susceptibility of the prodrug toward enzymatic degradation (peptidases) in cell culture and in vivo.


We have chosen a prodrug of nonapeptide GILGFVFTL (**2a**) as a target of this study. Parent nona-

* Send correspondence to this author at the Barbara Ann Karmanos Cancer Institute, 110 E. Warren Ave., Detroit, MI 48201-1379. Telephone: (313) 833-0715 x2452. Fax: (313) 832-7294. E-mail: zemlicka@kci.wayne.edu.

[†] Wayne State University School of Medicine.

[‡] Wayne State University.

Chart 1




peptide **2b** is an influenza matrix peptide 58–66 which was shown to be optimal for binding to HLA-2 and presentation to cytotoxic T lymphocytes.¹⁷ This article deals with the synthesis and biological investigation of peptide prodrug **2a**.


Synthesis

Although methods for *N*-glycopeptide assembly based on solution- or solid-phase peptide synthesis are available,¹⁸ examples of carbohydrates linked to an *N*-terminus of a peptide through a spacer are rare. In one instance, a β -D-galactopyranosyl-(1 \rightarrow 4)- β -D-glucopyranoside moiety was attached through a butyryl spacer to a neutral tricosapeptide in the last step of solid-phase synthesis.¹⁹ Because nonapeptide **2b** is commercially available, a possibility of direct introduction of β -D-glucuronyl-3-nitrobenzyloxycarbonyl spacer to the *N*-terminus of **2b** was considered first.

Several model experiments were conducted to determine feasibility of such an approach. Reaction of methyl 2,3,4-tri-*O*-acetyl- β -D-glucuronyl-3-nitrobenzyl alcohol (**3**), *N,N*-disuccinimidyl carbonate (DSC),⁸ and AlaOMe in the presence of triethylamine gave smoothly compound **4a** in 62% yield (Scheme 1). In a similar vein, free amino acids Gly, Phe, and Thr were converted to conjugates **4b–4d** in 66–83% yield. Transformation of dipeptides Phe-Leu and Leu-Arg to compounds **4e** and **4f** in 56 and 41% yield, respectively, was also uneventful. Interestingly, in case of Leu-Arg, attachment of the prodrug moiety occurred at the *N*-terminus as evidenced

Scheme 1^a


^a Reagents and conditions: (a) (1) *N,N*-disuccinyliminocarbonate (DSC), MeCN, NEt_3 , (2) R , NEt_3 , DMF; (b) MeONa, MeOH; (c) PLE, pH 7.2; (d) β -glucuronidase, pH 7.2.

Scheme 2^a

^a Reagents and conditions: (a) C_6F_5OH , DCC, DMF; (b) NEt_3 , DMF-THF (1:1); (c) PLE, pH 7.2; (d) $Ba(OH)_2$, MeOH; (e) β -glucuronidase, pH 7.2.

by ¹H NMR spectrum and negative reaction with ninhydrin. This can be explained by a protection of arginine moiety (stronger base than triethylamine) by protonation.²⁰ Deacetylation⁸ of conjugates **4b** and **4e** with MeONa in MeOH was also problem-free. Compounds **5b** and **5e** were obtained in 79 and 76% yield, respectively. Methyl glucuronate **5e** was hydrolyzed by pig liver esterase (PLE) to give 91% of glucuronic acid derivative **6e**. The latter compound was quantitatively digested by β -glucuronidase from *Escherichia coli* to give β -glucuronic acid (**7**), alcohol **8**, and Phe-Leu.

Although these experiments have indicated that a direct introduction of a glucuronyl prodrug residue into *N*-termini of amino acids or dipeptides is possible, application to nonapeptide **2b** was beset with problems from the very beginning. Reaction of **2b** with DSC and glucuronyl linker **3** led to formation of a complex mixture of products as shown by HPLC. Although mass spectrum showed that the desired prodrug **2a** was also present, preparative separation would be extremely difficult. Therefore, an alternate synthetic approach was devised. Because unprotected carbohydrate moieties interfere neither with the active ester formation nor peptide bond synthesis,^{21,22} it was anticipated that glycine conjugate **5b** can be used for introducing the prodrug function into octapeptide ILGFVFTL (**9**). As an

Scheme 3^a

^a Reagents and conditions: (a) DCC, HOBT, THF-DMF, 0 °C; (b) HCO₂H; (c) H₂, Pd/C, EtOH; (d) EDCl, HOBT, THF-DMF, 0 °C; (e) (1) H₂, Pd/C, AcOH, (2) TFA. [EDCl, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride.]

additional advantage, no deprotection of the glucuronate moiety in the latter stages of prodrug synthesis would be necessary. In a model experiment, conjugate **5b** was converted to pentafluorophenyl ester **10** (91%, Scheme 2) which was then reacted with PheLeu to give intermediate **11a** in 63% yield. Digestion with PLE gave glucuronic acid conjugate **12** (91%). A similar cleavage of glucuronate prodrugs was described.^{23,24} Compound **12** was readily degraded by β -glucuronidase from bovine liver to give alcohol **8** and Gly-Phe-Leu.

Next, octapeptide **9** was prepared by a racemization-free fragment coupling strategy^{25,26} (Scheme 3). Joining of protected amino acid derivatives **13** and **15** gave dipeptide **14** (84%) which was deprotected to give **16** (87%). Coupling with Boc-Phe-OH (**18**) gave tripeptide **17** (77%). Deprotection afforded tripeptide fragment **19** (82%). In a similar fashion, Boc-Phe-OH (**18**) was coupled with Val-OBn (**20**) to furnish dipeptide **21** (81%). Debenzylation led to **22** (90%) which was converted to pentapeptide **23** by condensation with tripeptide **19** (70%). Deprotection then afforded pentapeptide **24** (90%), a key fragment for synthesis of octapeptide **9**. Dipeptide **26** was prepared from Gly-OBn (**25**) and Boc-Leu-OH (**27**) in 87% yield. Deprotection of **26** gave dipeptide **28** (85%) which was extended to tripeptide **29** (77%) with Boc-Ile-OH (**30**). Debenzylation afforded a key tripeptide fragment **31** (85%). Coupling of both fragments **24** and **31** gave octapeptide **32** (66%) which was totally deprotected by hydrogenolysis in AcOH followed by treatment with TFA to give ILGFVFTL (**9**) in 62% yield.

Condensation of **10** with octapeptide **9** gave the methyl ester of the prodrug **11b** (36%). In contrast to dipeptide **5e** and tripeptide **11a**, the nonapeptide ester prodrug **11b** was a poor substrate for PLE. Therefore, ester **11b** was hydrolyzed with Ba(OH)₂ in MeOH²⁴ to give target prodrug **2a** (37%). Digestion of **2a** with β -glucuronidase from bovine liver gave benzyl alcohol **8** and nonapeptide **2b** which were identical with authentic samples.

Biological Studies

Binding of nonapeptide **2b** and prodrug **2a** to HLA-A2.1 was investigated with T2 human cells defective in




Figure 1. A total of 3×10^5 T2 cells were incubated with nonapeptide **2b** (solid diamonds) or prodrug **2a** (open circles) at concentrations of 15 to 120 μ M as indicated. *E. coli* β -glucuronidase at 200 (open squares) or 300 μ M (solid triangles) was added to mixtures containing cells and prodrug **2a**. For other details, see Experimental Section.

MHC I-associated peptide processing.²⁷ Because of the defect, HLA-A2.1 on these cells do not contain endogenous peptides, are unstable, and promptly degraded, resulting in a low level of HLA-A2.1 on the surface. Binding of exogenous peptides to A2.1 gives stable MHC/peptide complexes and increased level of surface HLA-A2.1 which can be detected by flow cytometry.

Nonapeptide **2b** binds to T2 cells in a dose-dependent manner in the range of 15 to 60 μ M. At 60 μ M of **2b**, the HLA-A2.1 level increased to 230% of control cells which were incubated without peptide or β -glucuronidase at pH 6.5–7.0 to approach the physiological conditions. The enzyme alone did not affect the level of HLA-A2.1 (data not shown). Incubation of nonapeptide prodrug **2a** up to the 120 μ M level without β -glucuronidase had no effect on HLA-A2.1, indicating a complete absence of binding (Figure 1). In the presence of 200 and 300 units/mL of β -glucuronidase, HLA-A2.1 level increased with increasing concentration of the enzyme. At 300 units/mL of the enzyme and 120 μ M of prodrug **2a**, the HLA-A2.1 level increased to 210% of the control value. Therefore, β -glucuronidase liberated active

nonapeptide **2b** from prodrug **2b**. Although this pH may not be optimal²⁸ for the activity of β -glucuronidase in a tumor environment, there is a significant release of active nonapeptide **2b** to mark the cells. Further biological investigations are in progress.

Conclusion

We have elaborated two basic strategies for introduction of prodrug grouping, which can be activated by β -glucuronidase, into amino acids and peptides. This effort culminated in the synthesis of the first prodrug of antigenic nonapeptide GILGFVFTL (compound **2a**). Nonapeptide **2b** released from **2a** by the action of β -glucuronidase binds to T2 cells in a dose-dependent manner but it is inactive in the absence of the enzyme. This has demonstrated that a prodrug therapy concept previously employed in the context of antitumor anthracycline antibiotics is applicable to exogenous antigenic peptides to mark tumor cells for immune destruction.

Experimental Section

General Methods. NMR spectra were determined at 400 MHz in DMSO-*d*₆. Optical rotations were determined with a JASCO DIP-370 digital polarimeter. Mass spectrometry was performed in electron-impact (EI) mode on KRATOS MS80, fast-atom bombardment (FAB) mode on KRATOS MS50, or electrospray ionization (ESI) mode on MICROMASS QUATTRO LC-MS. The TLC was run on 6 × 2 cm precoated aluminum sheets of silica gel 60 F₂₅₄, layer thickness 0.2 mm (E. Merck, Darmstadt, Germany), in the following solvents: S₁, CH₂Cl₂-MeOH (9:1); S₂, CH₂Cl₂-MeOH (4:1); S₃, CH₂Cl₂-MeOH-NH₄OH (6:4:0.1); S₄, CH₂Cl₂-MeOH (3:2); S₅, CH₂Cl₂-THF (4:1); S₆, CH₂Cl₂-MeOH (7:3); S₇, BuOH-AcOH-H₂O (8:1:1); and S₈, CH₂Cl₂-MeOH (20:1). HPLC was performed with Waters C-18 column, 3.9 × 300 mm, or Phenomenex Aqua C-18 column, 4.6 × 250 mm, detection at 220 nm, flow rate 0.5 mL/min unless indicated otherwise. With the Waters column the following solvents were used: S₉, MeCN-H₂O (3:2, 0.1% TFA); S₁₀, MeCN-0.02 M NaH₂PO₄ (pH 4.0, 2:3); S₁₁, MeOH-H₂O (4:1); S₁₂, MeOH-H₂O (9:1); S₁₃, MeOH-H₂O (65:35); S₁₄, MeCN-H₂O (4:1, 0.1% TFA). Phenomenex column was employed with solvent S₁₅, MeCN-H₂O (1:1, 0.1% TFA), and S₁₆, MeCN-H₂O (45:55, 0.1% TFA). Nonapeptide GILGFVFTL was purchased from Genemed, Inc., San Francisco, CA. Glucuronide **3** was prepared as described.⁸ Pig liver esterase (PLE, EC 3.1.1.1), β -glucuronidase (EC 3.2.1.31) from *E. coli* (type X-A), and bovine liver (type B-1) were products of Sigma, St. Louis, MO.

Methyl N-[(2,3,4-Tri-O-acetyl)- β -D-glucopyranuronate-3-nitrobenzyloxycarbonyl]-L-alanine Methyl Ester (4a). Triethylamine (0.45 mL, 3.29 mmol) was added to a stirred solution of glucuronide **3** (0.5 g, 1.02 mmol) and *N,N'*-disuccinimidyl carbonate (DSC, 0.42 g, 1.64 mmol) in MeCN (5 mL) at room temperature. The progress of reaction was monitored on TLC (CH₂Cl₂-THF, 9:1). The starting material **3** was consumed after 2 h. A solution of AlaOMe-HCl (0.15 g, 1.02 mmol) and NEt₃ (0.143 mL, 1.02 mmol) in THF (5 mL) was then added. The mixture was stirred at room temperature for 16 h, solvent was evaporated, and residue was dissolved in CH₂Cl₂ (150 mL). The organic layer was washed with brine and water (50 mL each), dried (Na₂SO₄), and evaporated. Column chromatography on silica gel using solvent S₁ gave product **4a** (0.385 g, 62%): mp 155–156 °C; $[\alpha]^{25}_D$ 36° (c 1, CHCl₃); TLC, *R*_f 0.82 (S₁); HPLC (S₉, flow rate 1.0 mL/min, *t*_R 7.98 min, purity 95%); ¹H NMR (CDCl₃) δ 7.81 (s, 1H), 7.52 (d, 1H) and 7.35 (d, 1H), 7.25 (s, 1H), 5.33 (m, 3H), 5.19 (d, 1H) and 4.19 (d, 1H), 5.09 (s, 2H), 4.36 (m, 1H), 3.74 and 3.75 (2s, 6H), 2.12, 2.06 and 2.05 (3s, 9H), 1.42 (d, 3H); FAB-MS (NaCl) 637 (M + Na). Anal. C₂₅H₃₀N₂O₁₆ (C, H, N).

Methyl N-[(2,3,4-Tri-O-acetyl)- β -D-glucopyranuronate-3-nitrobenzyloxycarbonyl]glycine (4b). The reaction of glucuronide **3** (0.25 g, 0.51 mmol) with DSC was performed as described for alaninate **4a**. A solution of glycine (38 mg, 0.51 mmol) and NEt₃ (71 μ L, 0.51 mmol) in DMF (5 mL) was added to the mixture which was stirred at room temperature for 16 h. After evaporation, ethyl acetate (100 mL) was added, and the workup followed the procedure for **4a**. Chromatography using solvent S₂ afforded compound **4b** (0.25 g, 83%): mp 94–96 °C; $[\alpha]^{25}_D$ 15.0° (c 0.1, MeOH); TLC, *R*_f 0.56 (S₆); HPLC (S₁₀, *t*_R 10.3 min, purity 90%); ¹H NMR δ 12.59 (bs, 1H), 7.87 (s, 1H), 7.67–7.57 (m, 2H), 7.40 (d, 1H), 5.72 (d, 1H), 5.43 (t, 1H), 5.11–5.06 (m, 2H), 4.72 (d, 1H), 5.03 (s, 2H), 3.63 (m, 5H), 1.98 (bs, 9H); FAB-MS (KCl) 625 (M + K). Anal. Calcd for C₂₃H₂₆N₂O₁₆: C, 47.09; H, 4.47; N, 4.78. Found C, 47.15; H, 4.61; N, 4.75.

Methyl N-[(2,3,4-Tri-O-acetyl)- β -D-glucopyranuronate-3-nitrobenzyloxycarbonyl]-L-phenylalanine (4c). The procedure described for compound **4a** was performed on a 0.41 mmol scale of L-phenylalanine. Chromatography of the crude product using solvent S₂ provided product **4c** (0.175 g, 66%): mp 126–127 °C; $[\alpha]^{25}_D$ 18° (c 0.5, CHCl₃); TLC, *R*_f 0.65 (S₂); HPLC (S₁₀, *t*_R 3.9 min, purity 94%); ¹H NMR (CDCl₃) δ 7.74 (s, 1H), 7.45 (d, 1H) and 7.32 (d, 1H), 7.26 (bs, 5H), 7.15 (d, 1H), 5.35–5.18 (m, 4H), 4.24 (d, 1H), 5.04 (s, 2H), 4.64 (m, 1H), 3.72 (s, 3H), 3.12 (m, 2), 2.17, 2.11 and 2.05 (3s, 9H); FAB-MS (KCl) 715 (M + K). Anal. C₃₀H₃₂N₂O₁₆ (C, H, N).

Methyl N-[(2,3,4-Tri-O-acetyl)- β -D-glucopyranuronate-3-nitrobenzyloxycarbonyl]-L-threonine (4d). The reaction was performed on 0.82 mmol scale with L-threonine as described above for compound **4a**. Chromatography using solvent S₆ as eluent gave product **4d** (0.38 g, 73%): mp 90–92 °C; $[\alpha]^{25}_D$ 8.2° (c 0.5, CHCl₃); TLC, *R*_f = 0.50 (S₃); HPLC (S₁₀, *t*_R 10.0 min, purity 82%); ¹H NMR (300 MHz) δ 7.90 (bd, 1H), 7.68 (d, 1H) and 7.41 (d, 1H), 7.08 (d, 1H), 5.73 (d, 1H), 5.43 (t, 1H) and 5.12–5.02 (m, 4H) and 4.72 (d, 1H), 4.05 (m, 1H), 3.93 (m, 1H), 3.62 (s, 3H), 2.02, 2.01 and 1.98 (3s, 9H), 1.07 (d, 3H); FAB-MS 631 (M + H). Anal. C₂₅H₃₀N₂O₁₇ (C, H, N).

Methyl N-[(2,3,4-Tri-O-acetyl)- β -D-glucopyranuronate-3-nitrobenzyloxycarbonyl]-L-phenylalanyl-L-leucine (4e). The procedure described above for alaninate **4a** was followed on 2.06 mmol scale of Phe-Leu. Column chromatography on silica gel using solvent S₂ afforded product **4e** (0.9 g, 56%): mp 110–111 °C; $[\alpha]^{25}_D$ 42° (c 1, EtOH); TLC, *R*_f 0.79 (S₂); HPLC (S₉, *t*_R 13.3, flow rate 1.0 mL/min, purity 90%); ¹H NMR δ 8.28 (d, 1H), 7.76 (s, 1H) and 7.56 (d, 1H), 7.45 (d, 1H), 7.15 (d, 1H), 7.34–7.18 (m, 5H), 5.72 (d, 1H), 5.44 (t, 1H), 5.10 (m, 2H) and 4.74 (d, 1H), 4.91 (s, 2H), 4.29–4.19 (m, 2H), 3.62 (s, 3H), 3.00–2.64 (m, 2H), 2.06, 1.99 and 1.97 (3s, 9H), 1.62–1.46 (m, 3H), 0.88–0.81 (dd, 6H); FAB-MS 790 (M + H). Anal. C₃₆H₄₃N₃O₁₇ (C, H, N).

Methyl N-[(2,3,4-Tri-O-acetyl)- β -D-glucopyranuronate-3-nitrobenzyloxycarbonyl]-L-leucyl-L-arginine (4f). The reaction was as described for alaninate **4a** on 0.2 mmol scale of Leu-Arg acetate. Chromatography using solvent S₂ gave product **4f** (67 mg, 40.9%): mp 110°; $[\alpha]^{25}_D$ 8° (c 0.4, CHCl₃); *R*_f 0.79 (S₂); HPLC (S₁₀, *t*_R 7.23 min, purity 84%); ¹H NMR δ 9.28 (bs, 1H), 7.88 (s, 1H), 7.66 (2d, 3H), 7.44–7.34 (d, 4H), 5.71 (d, 1H), 5.41 (t, 1H), 5.12–4.91 (m, 4H), 4.71 (d, 1H), 3.98 (d, 1H), 3.82 (d, 1H), 3.61 (s, 3H), 2.98 (bs, 2), 2.00, 1.98 and 1.97 (3s, 9H), 1.62–1.38 (m, 7H), 0.79 (dd, 6H); FAB-MS 799 (M + H). Anal. C₃₃H₄₆N₆O₁₇·2H₂O (C, H, N, -0.44).

Methyl N-[(β -D-Glucopyranuronate-3-nitrobenzyloxycarbonyl]glycine (5b). Freshly prepared MeONa (0.79 mmol) in MeOH (2 mL) was added with stirring to a solution of compound **4b** (0.5 g, 0.63 mmol) in MeOH (20 mL) at 0 °C. The progress of deacetylation was monitored by TLC (S₄) and HPLC (S₁₀, flow rate 0.8 mL/min). The starting material was consumed in 30 min. Dowex 50 (H⁺ form, 0.25 g) was added, the mixture was filtered, and solvent was evaporated. Chromatography of the residue using solvent S₄ afforded product **5b** (0.320 g, 79%): mp 88–89 °C; $[\alpha]^{25}_D$ -25° (c 0.1, MeOH); TLC, *R*_f 0.50 (S₃); HPLC (S₁₅, *t*_R 5.3 min, purity 99%); ¹H NMR

δ 7.88 (s, 1H), 7.66 (d, 1H) and 7.52 (d, 1H), 7.15 (bs, 1H), 6.05 (d, 1H), 5.86 (d, 1H), 4.03 (t, 1H), 3.78 (t, 1H), 3.48 (d, 1H), 5.02 (s, 2H), 3.68 (s, 3H), 3.42–3.35 (m, 6H); ESI-MS (NaCl) 483 (M + Na). Anal. $C_{17}H_{20}N_2O_{13} \cdot H_2O$ (C, H, N).

Methyl *N*-[β -D-Glucopyranuronate-3-nitrobenzyloxy-carbonyl]-L-phenylalanyl-L-leucine (5e). The reaction with triacetate **4e** was performed as described for compound **5b** to give product **5e** (0.32 g, 76%): mp 142–143 °C; $[\alpha]^{25}_D$ –38.8° (c 0.5, EtOH); TLC, R_f 0.51 (S_3); HPLC (S_{10} , flow rate 0.8 mL/min, t_R 10.1 min, purity 85%); 1H NMR δ 8.26 (d, 1H), 7.74 (s, 1H) and 7.53 (d, 1H), 7.44 and 7.37 (2d, 2H), 7.29–7.12 (m, 5H), 5.53–5.49 (3 overlapped s, 3H), 4.90 (s, 2H), 5.29 (apparent d, 2H), 4.12 (d, 1H), 4.29–4.19 (m, 2H), 3.63 (s, 3H), 3.00–2.57 (m, 2H), 1.6–1.46 (m, 3H), 0.89–0.81 (dd, 6H); FAB-MS (KCl) 702 (M + K). Anal. $C_{30}H_{37}N_3O_{14}$ (C, H, N).

***N*-[β -D-(Glucopyranuronic acid)-3-nitrobenzyloxy-carbonyl]-L-phenylalanyl-L-leucine (6e).** Compound **5e** (14.5 mg, 21 μ mol) in 0.02 M Na_2HPO_4 (pH 7.2, 10 mL) was incubated with PLE (1,200 units) at 37 °C. Progress of the reaction was monitored by HPLC (MeCN– NaH_2PO_4 , pH 4.0, 3:7, flow rate 0.6 mL/min). The starting material was consumed in 1 h with the formation of a new peak (t_R 5.6 min). The pH was adjusted to 4.0 with HCl, and the mixture was extracted with ethyl acetate. The organic phase was washed with water, it was dried (Na_2SO_4), and the solvent was evaporated to give compound **6e** (13 mg, 91%): mp 122–124 °C; $[\alpha]^{25}_D$ –14° (c 0.25, EtOH); TLC, R_f 0.42 (S_3); HPLC (S_{10} , flow rate 0.8 mL/min, t_R 5.6 min, purity 95%); 1H NMR δ 8.25 (d, 1H), 7.74 (s, 1H) and 7.53 (d, 1H), 7.43 (d, 1H) and 7.34 (d, 1H), 7.27–7.15 (m, 5H), 5.48 (d, 1H), 4.42 (d, 1H), 3.94 (m, 2H) and 3.25 (d, 1H), 5.24 (3 overlapped s, 3H), 4.90 (s, 2H), 4.24 (m, 2), 3.00–2.96 (m, 2H), 1.65–1.49 (m, 3H), 0.84 (dd, 6H); FAB-MS (KCl) 688 (M + K). Anal. $C_{29}H_{35}N_3O_{14}$ (C, H, N).

Digestion of Compound 6e with β -Glucuronidase. Compound **6e** (1 mg, 1.5 μ mol) and *E. coli* β -glucuronidase (800 units) were incubated in 0.02 M Na_2HPO_4 (pH 7.2, 1 mL) at 37 °C. Progress of reaction was monitored by HPLC (MeCN–0.02 M NaH_2PO_4 (pH 4.0) 3:7, flow rate 0.6 mL/min). The starting material was consumed within 1 h with the formation of Phe-Leu and 4-hydroxy-3-nitrobenzyl alcohol (**8**) whose t_R 's (4.8 and 9.7 min, respectively) were identical with those of the corresponding authentic samples.

Methyl *N*-[β -D-Glucopyranuronate-3-nitrobenzyloxy-carbonyl]glycyl-L-phenylalanyl-L-leucine (10). DCC (0.138 g, 0.67 mmol) and pentafluorophenol (0.124 g, 0.67 mmol) were added to a solution of compound **5b** (0.31 g, 0.67 mmol) in DMF–THF (1:5, 30 mL) at 0 °C. The mixture was stirred for 2 h at 0 °C and then at room temperature for 16 h. The solvents were evaporated, the residue was dissolved in EtOAc (50 mL), the solution was filtered, and the filtrate was evaporated. Chromatography on a silica gel column using hexane:EtOAc (1:4) as eluent gave 0.385 g (91%) of product **10**, which was used for the next coupling reaction: mp 145–147 °C; $[\alpha]^{25}_D$ –31° (c 0.1, MeOH); TLC, R_f 0.8 (S_5); HPLC (S_{11} , flow rate 0.8 mL/min, t_R 4.8 min, purity 84%); 1H NMR δ 7.80 (s, 1H), 7.59 (d, 1H) and 7.38 (d, 1H), 5.26 (d, 1H), 4.24 (bs, 2H), 4.07 (d, 1H), 3.04 (m, 3H), 5.02 (s, 2H), 3.61 (s, 3H), 3.36–3.24 (m, 3H); FAB-MS (NaCl) 649 (M + Na).

Methyl *N*-[β -D-Glucopyranuronate-3-nitrobenzyloxy-carbonyl]glycyl-L-phenylalanyl-L-leucine (11a). A solution of pentafluorophenyl ester **10** (0.1 g, 0.159 mmol) in THF (5 mL) was added with stirring to Phe-Leu (45 mg, 0.159 mmol) and NEt_3 (25 μ L, 0.159 mmol) in DMF (5 mL) at room temperature. The stirring was continued for 16 h, the solvents were evaporated, and residue was chromatographed on a silica gel column using solvent S_6 to give compound **11a** (72 mg, 63%): mp 160–161 °C, $[\alpha]^{25}_D$ –27° (c 0.1, MeOH); TLC, R_f 0.50 (S_4); HPLC (S_{10} , t_R 11.0 min, purity 93%); 1H NMR δ 8.24 (d, 1H), 8.01 (d, 1H), 7.82 (s, 1H), 7.59 (d, 1H), 7.43 (m, 2H), 7.19 (m, 5H), 5.50 (bs, 2H), 5.30 (d, 2H), 4.10 (d, 1H), 3.57 (d, 1H), 3.52 (bs, 1H), 4.98 (s, 2H), 4.53 (q, 1H), 4.35 (bs, 1H), 4.16 (q, 1H), 3.62 (s, 3H), 3.38 (bs, 2H), 3.00 (dd, 2H), 2.72 (m, 1H),

1.51–1.61 (m, 3H), 0.85 (dd, 6H); ESI-MS (NaCl) 743 (M + Na).

***N*-[β -D-(Glucopyranuronic acid)-3-nitrobenzyloxy-carbonyl]glycyl-L-phenylalanyl-L-leucine (12).** Compound **11a** (20 mg, 28 μ mol) and PLE (1,200 units) were incubated in Na_2HPO_4 (0.02 M, pH 7.2, 10 mL) at 37 °C. Progress of reaction was monitored by HPLC (S_{10} , flow rate 0.4 mL/min). The starting material was consumed in 1 h with the formation of a new major peak with t_R 7.2. The pH was adjusted to 4.0 with HCl, the mixture was partitioned between ethyl acetate and water, and the organic phase was dried (Na_2SO_4) and evaporated: yield 18 mg (91%) of tripeptide derivative **12**; mp 171–173 °C; $[\alpha]^{25}_D$ –14° (c 0.1, MeOH); TLC, R_f 0.49 (S_3); HPLC (S_{10} , flow rate 0.6 mL/min, t_R 7.4 min, purity 95%); 1H NMR δ 12.62 (bs, 1H), 8.28 (d, 1H), 8.00 (d, 1H), 7.83 (s, 1H), 7.59 (d, 1H) and 7.43 (m, 2H), 7.18 (m, 5H), 5.49 (bs, 1H), 5.25 (bs, 2H), 4.98 (s, 2H), 4.54 (q, 1H), 4.21 (q, 1H), 4.01–3.92 (m, 2H), 3.62–3.44 (m, 3H), 3.00 (dd, 2H), 2.72 (m, 1H), 1.51–1.61 (m, 3), 0.85 (dd, 6H); ESI-MS (NaCl) 729 (M + Na). Anal. $C_{31}H_{38}N_4O_{15}$ (C, H, N).

Digestion of Compound 12 by β -Glucuronidase. Compound **12** (1 mg, 1.4 μ mol) was incubated with bovine liver β -glucuronidase (800 units) in phosphate buffer (0.02 M, pH 7.2, 1 mL) at 37 °C. The reaction was followed by HPLC (S_{10} , flow rate 0.6 mL/min). The starting material was consumed in 4 h with the formation of two major peaks at t_R 6.5 (Gly-Phe-Leu) and 14.0 (compound **8**).

H-Leu-OBn (13). Free base **13** was released from the commercially available tosylate using $NaHCO_3$ (pH 8.0) and extracted with ethyl acetate as a thick oil (5.1 g, 92%): R_f 0.6 (S_7); 1H NMR δ 7.34 (bs, 5H), 5.07 (bs, 2H), 3.30 (bs, 1H), 1.71–1.66 (m, 3H), 1.40–1.29 (m, 2H), 0.82 (m, 6H); EI-MS 221 (M + H).

Boc-Thr(Bn)-Leu-OBn (14). HOBT (2.19 g, 16.16 mmol) and DCC (3.32 g, 16.16 mmol) were added with stirring to a solution of Boc-Thr(Bn)-OH (**15**, 5 g, 16.16 mmol) in THF (50 mL) at 0 °C. The stirring was continued for 30 min. The H-Leu-OBn (**13**, 4.46 g, 20.20 mmol) in DMF (30 mL) cooled to 0 °C was then added, and the mixture was stirred for 2 h and at room temperature for 16 h. The solvents were evaporated, the residue was dissolved in EtOAc (125 mL), and dicyclohexyl urea (DCU) was filtered off. The filtrate was washed twice with saturated aqueous $NaHCO_3$, 10% citric acid, and water (50 mL each); it was dried (Na_2SO_4) and evaporated. Chromatography using solvent S_8 as eluent gave dipeptide **14** (7.0 g, 84%): mp 84–85 °C, R_f 0.62 (S_8); 1H NMR δ 8.24 (d, 1H) and 6.59 (d, 1H), 7.33–7.24 (m, 10H), 5.07 (bs, 2H) and 4.35 (m, 2H), 4.49 (m, 1H), 4.05 (m, 1H), 3.79 (t, 1H), 1.58–1.47 (m, 3H), 1.36 (s, 9H), 1.07 (d, 3H), 0.78 (dd, 6H); EI-MS 512 (M).

H-Thr(Bn)-Leu-OBn (16). A solution of dipeptide **14** (6.5 g, 12.69 mmol) in HCO_2H (97%, 50 mL) was stirred at room temperature for 6 h. The solvent was evaporated, residue was dissolved in water (150 mL), and solution was extracted with ether (2 \times 50 mL). The pH of the aqueous phase was adjusted to 8.0 with aqueous $NaHCO_3$ and extracted with EtOAc (2 \times 100 mL). The organic portion was washed with water (50 mL), and it was dried (Na_2SO_4) and evaporated to give dipeptide **16** as a thick oil (4.6 g, 87%): R_f 0.72 (S_2); 1H NMR δ 8.56 (bs, 1H), 7.30 (2s, 10H), 5.09 (s, 2H), 4.50–4.35 (m, 4H), 3.81 (s, 1H), 1.58 (bs, 3H), 1.15–1.14 (d, 3H), 0.81 (dd, 6H); FAB-MS 413 (M + H).

Boc-Phe-Thr(Bn)-Leu-OBn (17). The reaction was performed as described for dipeptide **14** using Boc-Phe-OH (**18**, 3.66 g, 13.8 mmol), HOBT (1.87 g, 13.8 mmol), and DCC (2.84 g, 13.8 mmol) in THF (50 mL). Dipeptide **16** (3.8 g, 9.21 mmol) was then added in DMF solution (20 mL), and the mixture was stirred for 2 days at room temperature and worked-up as described for dipeptide **14**. Chromatography in CH_2Cl_2 :MeOH (10:1) furnished tripeptide **17** (4.7 g, 77%): mp 150–152 °C; R_f 0.64 (S_1); 1H NMR δ 8.24 (d, 1H), 7.82 (d, 1H) and 7.09 (d, 1H), 7.27 (m, 15H), 5.05 (dd, 2H), 4.48–4.35 (m, 4H), 4.23 (m, 1H), 3.90 (t, 1H), 2.95 (m, 1H), 2.71 (m, 1H), 1.54 (m, 3H), 1.25 (s, 9H), 1.08 (d, 3H), 0.82 (dd, 6H); FAB-MS (KCl) 698 (M + K).

• **H-Phe-Thr(Bn)-Leu-OBn (19).** It was prepared as described for dipeptide **16** from tripeptide **17** (4 g, 6.06 mmol). The tripeptide **19** (2.8 g, 82%) was obtained as a thick oil: TLC, R_f 0.71 (S_2); HPLC (S_{12}), flow rate 0.6 mL/min, t_R 6.6 min, 96% purity; 1H NMR δ 8.32 (d, 1H), 8.27 (d, 1H), 7.31–7.20 (m, 15H), 5.06 (dd, 2H), 4.47–4.36 (m, 5H), 3.90 (t, 1H), 3.69 (bs, 1H), 3.02 (m, 1H), 2.68 (m, 1H), 1.58–1.50 (m, 4H), 1.03 (d, 3H), 0.83 (dd, 6H); ESI-MS 560 (M + H).

H-Val-OBn (20). Free base was released from the corresponding hydrochloride as described for H-Leu-OBn (**13**) as a thick oil: R_f 0.7 (S_7); 1H NMR δ 7.33 (m, 5H), 5.12 (dd, 2H), 3.13 (d, 1H), 1.83 (m, 1H), 1.69 (bs, 2H), 0.80 (dd, 6H); EI-MS 207 (M + H).

Boc-Phe-Val-OBn (21). The reaction was performed as described for dipeptide **14** with Boc-Phe-OH (**18**, 5.0 g, 18.84 mmol) and H-Val-OBn (**20**, 5.49 g, 26.35 mmol) to give dipeptide **21** (7 g, 81%): mp 68–69 °C; R_f 0.48 (S_8); 1H NMR δ 8.17 (d, 1H), 7.38 (m, 10H), 6.95 (d, 1H), 5.11 (dd, 2H), 4.24 (t, 2H), 2.88 (m, 1H), 2.67 (t, 1H), 2.06 (m, 1H), 1.26 (s, 9H), 0.86 (m, 6H); EI-MS 454 (M).

Boc-Phe-Val-OH (22). Boc-Phe-Val-OBn (**21**, 4.0 g, 8.81 mmol) was hydrogenated in a Parr apparatus at 40 psi for 2 h in ethanol (50 mL) over Pd-C (10%, 0.42 g). The catalyst was filtered off, and the solvent was evaporated. The residue was partitioned between aqueous $NaHCO_3$ (100 mL) and ether (2 \times 50 mL). The mixture (pH 3) was extracted with ethyl acetate (2 \times 100 mL), and the organic phase was washed with water, dried (Na_2SO_4), and evaporated to give the dipeptide **22** (2.9 g, 90%); mp 77–78 °C; R_f 0.58 (S_7); HPLC (S_{12}), flow rate 0.6 mL/min, t_R 5.6 min, purity 97%; 1H NMR δ 7.88 (d, 1H), 7.23 (m, 5H), 6.96 (d, 1H), 4.23–4.14 (m, 2H), 2.93 (m, 1H), 2.71 (q, 1H), 2.05 (m, 1H), 1.26 (s, 9H), 0.87 (m, 6H); FAB-MS (KCl) 403 (M + K).

Boc-Phe-Val-Phe-Thr(Bn)-Leu-OBn (23). The reaction of dipeptide **22** (2.5 g, 7.01 mmol) with tripeptide **19** (2.8 g, 5.00 mmol) was performed as described for dipeptide **14**. Chromatography in solvent (S_8) furnished pentapeptide **23** (4.4 g, 70%): mp 80–81 °C; R_f 0.66 (S_2); HPLC (S_{14}), flow rate 0.6 mL/min, t_R 11.4 min, purity 90%; 1H NMR δ 8.19 (d, 1H), 8.12 (d, 1H), 8.02 (d, 1H) and 7.61 (d, 1H), 7.32–7.10 (m, 20H), 7.00 (d, 1H), 5.00 (dd, 2H), 4.70 (m, 1H), 4.47–4.36 (m, 6H), 4.21–4.11 (m, 2H), 3.89 (t, 1H), 3.00 (m, 1H), 2.87–2.63 (m, 2H), 1.90 (m, 1H), 1.53 (m, 2H), 1.25 (s, 9H), 1.05 (d, 3H), 0.82 (dd, 6H), 0.73 (m, 6H); ESI-MS (NaCl) 928 (M + Na).

H-Phe-Val-Phe-Thr(Bn)-Leu-OBn (24). Deprotection of pentapeptide **23** (0.5 g, 0.55 mmol) was performed as described for dipeptide **14** to afford free pentapeptide **24** (0.4 g, 90%): mp 147–148 °C; R_f 0.55 (S_2); HPLC (S_{14}), flow rate 0.6 mL/min, t_R 6.3 min, purity 96%; 1H NMR δ 8.25 (d, 1H), 8.14 (d, 1H), 8.02 (d, 1H) and 7.89 (d, 1H), 7.30–7.17 (m, 20H), 5.05 (dd, 2H), 4.68 (m, 1H), 4.47–4.36 (m, 6H), 4.16 (m, 2H), 3.90 (t, 1H), 2.95 (m, 1H), 2.75 (m, 2H), 1.89 (m, 1H), 1.52 (m, 4H), 1.05 (d, 3H), 0.82 (dd, 6H), 0.75–0.63 (dd, 6H); ESI-MS 806 (M + H).

H-Gly-OBn (25). Free base was released from the corresponding hydrochloride as described in the workup procedure for dipeptide **16** as a thick oil: R_f 0.50 (S_1); 1H NMR δ 7.38–7.30 (m, 5H), 5.11 (s, 2H), 3.87 (m, 2H), 1.89 (bs, 2H); ESI-MS 165 (M + H).

Boc-Leu-Gly-OBn (26). It was prepared as described for dipeptide **14** from Boc-Leu-OH (**27**, 5 g, 20.05 mmol) and Gly-OBn (**25**, 4.13 g, 25.06 mmol). Chromatography afforded dipeptide **26** as a thick oil (7.0 g, 87%): R_f 0.90 (S_8); 1H NMR δ 8.26 (t, 1H), 7.32 (m, 5H), 6.89 (d, 1H), 5.09 (s, 2H), 3.91–3.82 (m, 3H), 1.60 (m, 1H), 1.34 (s, 11H), 0.81 (m, 6H); FAB-MS (KCl) 417 (M + K).

H-Leu-Gly-OBn (28). Deprotection of **26** (8 g, 21.16 mmol) was performed as described for dipeptide **14** to give **28** (5.88 g, 85%): R_f 0.51 (S_6); 1H NMR δ 8.60 (bs, 1H), 7.34 (s, 5H), 5.10 (s, 2H), 3.91 (ddd, 2H), 3.40 (t, 1H), 1.69 (bs, 2H), 1.44 (m, 1H), 1.30 (m, 2H), 0.83 (m, 6H); ESI-MS 279 (M + H).

Boc-Ile-Leu-Gly-OBn (29). This tripeptide was prepared as described for dipeptide **14** from Boc-Ile-OH (**30**, 2.50 g, 10.80 mmol) and dipeptide **28** (2.5 g, 8.99 mmol). Chromatography

gave tripeptide **29** (5.31 g, 77%): mp 50–51 °C; R_f 0.62 (S_8); 1H NMR δ 8.40 (bs, 1H), 7.79 (d, 1H), 7.33 (s, 5H), 6.80 (d, 1H), 5.08 (s, 2H), 4.36 (m, 1H), 3.94–3.73 (m, 3H), 1.62 (bs, 2H), 1.34 (s, 9H), 1.04 (m, 2H), 0.83–0.77 (m, 14H); ESI-MS 492 (M + H).

Boc-Ile-Leu-Gly-OH (31). Tripeptide **29** (2.0 g, 4.07 mmol) was hydrogenated in ethanol (25 mL) over Pd-C (10%, 0.2 g) as described for dipeptide **22** to give tripeptide **31** (1.4 g, 85%): mp 108–109 °C; R_f 0.69 (S_1); HPLC (S_{13}), flow rate 0.8 mL/min, t_R 7.9, purity 98.5%; 1H NMR δ 8.18 (bs, 1H), 7.79 (d, 1H), 6.82 (d, 1H), 4.36 (m, 1H), 3.77–3.62 (m, 3H), 1.63 (bs, 2H), 1.34 (s, 9H), 1.03 (m, 2H), 0.85–0.77 (m, 14H); ESI-MS 402 (M + H).

Boc-Ile-Leu-Gly-Phe-Val-Phe-Thr(Bn)-Leu-OBn (32). To a solution of tripeptide **31** (0.460 g, 1.02 mmol) in THF (20 mL) was added HOBT (0.14 g, 1.02 mmol) at 0 °C followed by 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI, 0.196 g, 1.02 mmol). The reaction mixture was stirred for 30 min. A cooled solution of pentapeptide **24** (0.46 g, 0.57 mmol) in DMF (10 mL) was then added. The stirring was continued at 0 °C for 2 h and at room temperature for 3 days. The mixture was worked up as described for the dipeptide **14**. Chromatography of the crude product in solvent S_8 provided octapeptide **32** (0.45 g, 66%): mp 177–179 °C; R_f 0.57 (S_8); HPLC (S_{14}), flow rate 0.6 mL/min, t_R 9.20, 91% purity; 1H NMR δ 8.11 (t, 2H), 8.03 (d, 1H), 7.98 (t, 1H), 7.92 (bs, 2H), 7.79 (d, 1H), 7.32–7.11 (m, 20H), 6.78 (d, 1H), 5.05 (dd, 2H), 4.70 (m, 1H), 4.55 (m, 1H), 4.47–4.36 (m, 4H), 4.27 (m, 1H), 4.13 (m, 1H), 3.89 (m, 2H), 3.59 (m, 2H), 2.80 (m, 4H), 1.34 (s, 9H), 1.56 (m, 3H), 1.05 (d, 3H), 0.83–0.77 (m, 26H); ESI-MS (NaCl) 1,211 (M + Na).

H-Ile-Leu-Gly-Phe-Val-Phe-Thr-Leu-OH (9). Octapeptide **32** (0.2 g, 4.07 mmol) was hydrogenated in AcOH (50 mL) over Pd-C (10%, 0.4 g) for 6 h. The catalyst was filtered off and the solvent evaporated. The residue was dissolved in TFA (10 mL), and the solution was stirred at room temperature for 1 h. The solvent was evaporated, and residue (0.14 g) was purified by HPLC using Phenomenex Aqua semipreparative column (10 \times 250 mm, S_{16} , flow rate 2.4 mL/min, t_R 7.4 min) to give octapeptide **9** (95 mg, 62%): mp 124–126 °C; R_f 0.63 (S_7); HPLC (S_{15}), t_R 4.2 min, flow rate 0.8 mL/min, purity 92%; 1H NMR δ 12.60 (bs, 1H), 8.43 (bs, 1H), 8.29 (d, 1H), 8.20 (bs, 1H), 8.07 (bs, 3H), 7.86 (bs, 1H), 7.20–7.14 (b, 10H), 4.79 (d, 1H), 4.61 (bs, 1H), 4.38 (m, 2H), 4.24–4.16 (m, 3H), 3.90 (bs, 1H), 3.76 (m, 1H), 3.61 (bs, 2H), 2.98 (m, 2H), 2.75 (m, 2H), 1.90 (m, 1H), 1.75 (m, 1H), 1.61–1.43 (m, 6H), 1.01 (bs, 3H), 0.86–0.72 (m, 26H); ESI-MS 909 (M + H).

Methyl N-[β -D-Glucopyranuronate-3-nitrobenzyloxy-carbonyl]-Gly-Ile-Leu-Gly-Phe-Val-Phe-Thr-Leu-OH (11b). A solution of pentafluorophenylester **10** (136 mg, 0.22 mmol) in THF (10 mL) was added to a mixture of octapeptide **9** (100 mg, 0.11 mmol) and NEt_3 (15 μ L, 0.11 mmol) in DMF (10 mL) with stirring at room temperature. The stirring was continued for 40 h, the solvents were evaporated, and residue was chromatographed (three times) using $CHCl_3$:MeOH (3:2) to obtain compound **11b** (68 mg, 46%) which was further purified by semipreparative HPLC (see octapeptide **9**, S_{16} , flow rate 3.4 mL/min) to give 52 mg (34%) of **11b**: HPLC (S_{16} , flow rate 1.0 mL/min, t_R 13.1, purity 86%); mp 140–142 °C; $[\alpha]_D^{25}$ 11° (c 0.1, MeOH); R_f 0.49 / $CHCl_3$:MeOH: NH_4OH (4:6:0.1); 1H NMR δ 8.11 (bs, 4H), 8.03 (bs, 1H), 7.98 (d, 1H), 7.93 (d, 1H), 7.88 (d, 1H), 7.83 (bs, 1H), 7.61 (d, 1H), 7.53 (bs, 1H), 7.41 (d, 1H), 7.26–7.11 (m, 10H), 5.54–5.50 (m, 2H), 5.30 (m, 2H), 4.99 (s, 2H), 4.66 and 4.52 (2m, 3H), 4.35 (bs, 1H), 4.25 (bs, 2H), 4.14–4.00 (m, 5H), 3.63 (s, 3H), 3.54 (d, 1H), 3.15 (d, 1H), 3.05 (m, 5H), 2.88–2.60 (m, 7H), 1.86 (m, 1H), 1.63 (m, 1H), 1.54 (m, 1H), 1.39 (m, 2H), 1.03 (m, 3H), 0.98 (d, 3H), 0.86–0.74 (m, 23H); Negative ESI-MS (NH_4OH) 1,349 (M – H).

N-[β -D-(Glucopyranuronic acid)-3-nitrobenzyl-carbonyl]-Gly-Ile-Leu-Gly-Phe-Val-Phe-Thr-Leu-OH (2a). A mixture of compound **11b** (20 mg, 0.014 mmol) and $Ba(OH)_2 \cdot 8H_2O$ (4.6 mg, 0.014 mmol) in MeOH (10 mL) was stirred at room temperature for 3 h. Dowex 50 (H^{+} form, 25 mg) was then added, and the mixture was filtered. The filtrate was evapo-

rated to give crude prodrug which was purified by semi-preparative HPLC (see octapeptide **9**, flow rate 3.4 mL/min) to give 9 mg (47%) of **2a**. Analytical HPLC (flow rate 1.0 mL/min, t_R 7.9 min, purity 76%): mp 180–181 °C, $[\alpha]_D^{26}$ 6.0° (c 0.1, MeOH); 1H NMR (500 MHz) δ 8.07 (d, 1H), 8.01 (d, 1H), 7.96–7.91 (m, 4H), 7.87 (d, 1H), 7.84 (s, 1H), 7.81 (d, 1H), 7.61 (d, 1H), 7.51 (bs, 1H), 7.42 (d, 1H), 7.25–7.31 (m, 10H), 5.48 (bs, 1H), 5.40 (bs, 1H), 5.26 (d, 2H), 5.00 (s, 2H), 4.78 (bs, 1H), 4.67 and 4.55 (2m, 4H), 4.24–4.12 (m, 6H), 3.96–3.91 (m, 2H), 3.60 (m, 2H), 3.03 (m, 2H), 2.89 (m, 2H), 2.79 (m, 2H), 2.66 (m, 2H), 2.53 (bs, 5H), 1.90 (m, 1H), 1.66 (m, 2H), 1.41 (m, 2H), 1.22 (bs, 3H), 1.03 (d, 3H), 0.88–0.74 (m, 26H); Negative ESI-MS (NH_4OH) 1,335 (M – H).

Hydrolysis of Peptide Prodrug **2a by β -Glucuronidase.** The hydrolysis of propeptide **2a** was performed as described for propeptide **12**. It was followed by HPLC (S_{16} , flow rate 1.0 mL/min). The starting material was consumed in 4 h with the formation of two peaks with t_R 3.6 and 4.5 min, corresponding to the authentic samples of 4-hydroxy-3-nitrobenzyl alcohol (**8**) and nonapeptide **2b**, respectively.

Binding of Nonapeptide **2b and Prodrug **2a** to HLA-A2.1.** T2 cells were maintained in AIM V medium (GIBCO BRL/Life Technologies, Gaithersburg, MD) containing 10% fetal calf serum. A total of 3×10^5 T2 cells were incubated in the medium with varying concentrations of **2b** or **2a**. To activate the prodrug **2a**, β -glucuronidase from *E. coli* (200 and 300 units/mL) was added to the cell culture. The pH was maintained at 6.6 ± 0.2 in this medium. The mixtures were incubated at 37 °C for 1 h and then at 28 °C overnight. To measure the level of HLA-A2.1, cells were stained with mouse monoclonal antibody BB7.2 (American Type Culture Collection). Unbound antibody was removed by extensive washing, and bound antibody was visualized by staining with fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse IgG (Jackson Immunological Research Laboratory, West Grove, PA). Isotype matched monoclonal antibody was the negative control. Flow cytometric analysis was performed with a FACS Calibur (Beckton Dickinson, San Jose, CA), and the data are recorded as mean channel fluorescence. The results (average from three separate experiments) are given in Figure 1.

Acknowledgment. This work was supported by a research grant DOD BC 980459 from U.S. Army, Department of Defense.

References

- (1) Preliminary report: Rawale, S.; Hrihorczuk, L. M.; Wei, W.-Z.; Zemlicka, J. Synthesis and Preliminary Biological Investigation of T-Cell Antigenic Peptide Prodrug Activated by β -Glucuronidase. *Abstracts of Papers*, 222nd National Meeting of the American Chemical Society, Chicago, Illinois, August 26–30, 2001; American Chemical Society: Washington, DC, 2001; CARB 110.
- (2) Bagshawe, K. D. Antibody Directed Enzymes Revive Anticancer Prodrug Concept. *Br. J. Cancer* **1987**, *56*, 531–532.
- (3) Bagshawe, K. D.; Sharma, S. K.; Burke, P. J.; Melton, R. G.; Knox, R. J. Developments with Targeted Enzymes in Cancer Therapy. *Curr. Opin. Immunol.* **1999**, *11*, 579–583.
- (4) Niculescu-Duvaz, I.; Spooner, R.; Marais, R.; Springer, C. J. Gene Directed Enzyme Prodrug Therapy. *Bioconjug. Chem.* **1998**, *9*, 4–22.
- (5) Andrianomenjanahary, S.; Dong, X.; Florent, J.-C.; Gaudel, G.; Gesson, J.-P.; Jacquesy, J.-C.; Koch, A.; Michel, S.; Mondon, M.; Monneret, C.; Petit, P.; Renoux, B.; Tillequin, F. Synthesis of Novel Targeted Pro-Drugs of Anthracyclines Potentially Activated by a Monoclonal Antibody Galactosidase Conjugate (Part 1). *Bioorg. Med. Chem. Lett.* **1992**, *2*, 1093–1096.
- (6) Gesson, J. P.; Jacquesy, J.-C.; Mondon, M.; Petit, P.; Renoux, B.; Andrianomenjanahary, S.; Dufat-Trinh Van, H.; Koch, M.; Michel, S.; Tillequin, F.; Florent, J.-C.; Monneret, C.; Bosslet, K.; Czech, J.; Hoffmann, D. Prodrugs of Anthracyclines for Chemotherapy Via Enzyme-Monoclonal Antibody Conjugates. *Anti-Cancer Drug Res.* **1994**, *9*, 409–423.
- (7) Azoulay, M.; Florent, J.-C.; Monneret, C.; Gesson, J. P.; Jacquesy, J.-C.; Tillequin, F.; Koch, M.; Czech, J.; Hoffmann, D. Prodrugs of Anthracycline Antibiotics Suited for Tumor-Specific Activation. *Anti-Cancer Drug Res.* **1995**, *10*, 441–450.
- (8) Florent, J.-C.; Dong, X.; Gaudel, G.; Mitaku, S.; Monneret, C.; Gesson, J.-P.; Jacquesy, J.-C.; Mondon, M.; Renoux, B.; Andrianomenjanahary, S.; Michel, S.; Koch, M.; Tillequin, F.; Gerken, M.; Czech, J.; Straub, R.; Bosslet, K. Prodrugs of Anthracyclines for Use in Antibody-Directed Enzyme Prodrug Therapy. *J. Med. Chem.* **1998**, *41*, 3572–3581.
- (9) Ghosh, A. K.; Khan, S.; Marini, F.; Nelson, J. A.; Farquhar, D. A Daunorubicin β -Galactoside Prodrug for Use in Conjunction with Gene-Directed Enzyme Prodrug Therapy. *Tetrahedron Lett.* **2000**, *41*, 4871–4874.
- (10) Bosslet, K.; Czech, J.; Hoffmann, D. A Novel One-Step Tumor-Selective Prodrug Activation System. *Tumor Targeting* **1995**, *1*, 45–50.
- (11) Murtter, T. E.; Sperker, B.; Kivisto, K. T.; McClellan, M.; Fritz, P.; Friedel, G.; Linder, A.; Bosslet, K.; Toomes, H.; Dierkesmann, R.; Kroemer, H. K. Enhanced Uptake of Doxorubicin into Bronchial Carcinoma: β -Glucuronidase Mediates Release of Doxorubicin from a Glucuronide Prodrug (HMR 1826) at the Tumor Site. *Cancer Res.* **1997**, *57*, 2440–2445.
- (12) Bosslet, K.; Straub, R.; Blumrich, M.; Czech, J.; Gerken, M.; Sperker, B.; Kroemer, H. K.; Gesson, J.-P.; Koch, M.; Monneret, C. Elucidation of the Mechanism Enabling Tumor Selective Prodrug Monotherapy. *Cancer Res.* **1998**, *58*, 1195–1201.
- (13) Davis, M. M.; Bjorkman, P. J. T-Cell Antigen Receptor Genes and T-Cell Recognition. *Nature* **1988**, *334*, 395–402.
- (14) Monaco, J. J. Pathways of Antigen Processing: A Molecular Model of MHC Class-I-Restricted Antigen Processing. *Immunol. Today* **1992**, *13*, 173–176.
- (15) Wei, W.-Z.; Gill, R. F.; Jones, R. F.; Lichlyter, D.; Abastado, J. P. Induction of Cytotoxic T Lymphocytes to Murine Mammary Tumor Cells with a Kd-Restricted Immunogenic Peptide. *Int. J. Cancer* **1996**, *66*, 659–663.
- (16) Poenaru, S.; Lamas, J. R.; Folkers, G.; Lopez de Castro, J. A.; Seebach, D.; Rognan, D. Nonapeptide Analogues Containing (R)-3-Hydroxybutanoate and β -Homocysteine Oligomers: Synthesis and Binding Affinity to a Class I Major Histocompatibility Complex Protein. *J. Med. Chem.* **1999**, *42*, 2318–2331.
- (17) Morrison, J.; Elvin, J.; Latron, F.; Gotch, F.; Moots, R.; Strominger, J. L.; McMichael, A. Identification of the Nonamer Peptide from Influenza A Matrix Protein and the Role of Pockets of HLA-2 in Its Recognition by Cytotoxic T Lymphocytes. *Eur. J. Immunol.* **1992**, *22*, 903–907.
- (18) Meldal, M. Glycopeptide Synthesis. In *Neoglycoconjugates: Preparation and Applications*; Lee, Y. C., Lee, R. T., Eds.; Academic Press: New York, 1994; pp 145–198, loc. cit. 158–165.
- (19) Ando, S.; Aikawa, J.-i.; Nakahara, Y.; Ogawa, T. Synthesis and Properties of Neoglycoconjugates Carrying a Dimerization Motif of Glycophorin A Transmembrane Domain. *J. Carbohydr. Chem.* **1998**, *17*, 633–645.
- (20) Bodanszky, M.; Klausner, Y. S.; Ondetti, M. A. *Peptide Synthesis*; John Wiley & Sons: New York, 1976; p 67.
- (21) Otvos, L., Jr.; Urge, L.; Hollosi, M.; Wroblewski, K.; Graczyk, G.; Fasman, G.; Thurin, J. Automated Solid-Phase Synthesis of Glycopeptides. Incorporation of Unprotected Mono- and Disaccharide Units of n-Glycoprotein Antennae Into T-Cell Epitopic Peptides. *Tetrahedron Lett.* **1990**, *31*, 5889–5892.
- (22) Reimer, K. B.; Meldal, M.; Kusumoto, S.; Fukase, K.; Bock, K. Small-Scale Solid-Phase O-Glycopeptide Synthesis of Linear and Cyclized Hexapeptides from Blood-Clotting Factor IX Containing O-(α -D-Xyl-1–3- α -D-Xyl-1–3- β -D-Glc)-L-Ser. *J. Chem. Soc., Perkin Trans. 1* **1993**, 925–932.
- (23) Ghosh, A. K.; Farquhar, D. A Methyl Glucuronate Prodrug of Phosphorodiamidic Mustard. *Tetrahedron Lett.* **2000**, *41*, 4871–4874.
- (24) Papot, S.; Combaud, D.; Gesson, J.-P. A New Spacer Group Derived from Arylmalonaldehydes for Glucuronylated Prodrugs. *Bioorg. Med. Chem. Lett.* **1998**, *8*, 2545–2548.
- (25) Bodanszky, M.; Bodanszky, A. *The Practice of Peptide Synthesis*; Springer-Verlag: New York, 1984; pp 153–171.
- (26) Datta, S.; Shamala, N.; Banerjee, A.; Pramanik, A.; Bhattacharya, S.; Balam, P. Characterization of Helix Terminating Schellman Motifs in Peptides. Crystal Structure and Nuclear Overhauser Effect Analysis of a Synthetic Heptapeptide Helix. *J. Am. Chem. Soc.* **1997**, *119*, 9246–9251.
- (27) Salter, R. D.; Creswell, P. Impaired Assembly and Transport of HLA-A and -B Antigens in a Mutant TxB Cell Hybrid. *Embo J.* **1986**, *5*, 943–949.
- (28) Voigt, K.-D.; Schmidt, H. Hydrolysis of Steroid Conjugates. In *Methods of Enzymatic Analysis*; Bergmeyer, H. U., Ed.; Academic Press: New York, 1974; Vol. 4, pp 1848–1857.

Era of Hope 2002 – abstract
DAMD 17-99-1-9244

**THERAPEUTIC PRODRUG OF HLA-A2.1 ASSOCIATED FLU PEPTIDE MP58
GILGFVFTL ACTIVATED BY β -GLUCURONIDASE**

Wei-Zen Wei, Sharad Rawale, Diego Laderach, *Lew M. Hrihorczuk, and Jiri Zemlicka.
Cancer Institute and *Dept of Chemistry, Wayne State University, Detroit, MI 48201

ABSTRACT: The long term goal is to test the hypothesis that cancer can be eliminated by immunizing the host with foreign peptides followed by systemic delivery of pro-peptides which are activated at the tumor site by tumor associated enzymes. To test the hypothesis, HLA-A2.1 restricted flu peptide MP58 is linked at the N-terminus to β -glucuronic acid which can be removed by β -glucuronidase. β -glucuronidase is a 310-380 Kd lysosomal enzyme with exoglycosidase activity and is liberated from necrotic tumor cells and tumor infiltrating monocytes to create a high concentration of extracellular β -glucuronidase in the tumor microenvironment. β -glucuronate was attached to the glycine moiety through a benzyloxycarbonyl linker. The product was reacted with octapeptide ILGFVFTL and the target prodrug β -Glu-MP58 was generated following ester hydrolysis. Incubation of the prodrug with β -glucuronidase triggers a self-destructive reaction to liberate free MP58 which was verified by HPLC. MP58 binds to HLA-A2.1 on human T2 cells in a dose dependent manner and A2.1 level increased by 230% in the presence of 60 mM MP58. When T2 cells were incubated with pro-peptide β -Glu-MP58 up to 120 mM, their A2.1 level did not change. In the presence of 300 units/ml of β -glucuronidase, A2.1 level increased by 210%, supporting the enzymatic liberation of active MP58 from the prodrug. An MP58 specific CTL line was established from peripheral blood monocytes of an A2.1 positive adult man by repeated stimulation with MP58 loaded antigen presenting cells. Over 80% of MP58 loaded T2 cells were lysed by CTL at E:T ratio of 10:1 – 2:1. The same CTL did not lyse T2 cells loaded with pro-peptide β -Glu-MP58. In the presence of β -glucuronidase, 80% of T2 cells were lysed, further demonstrating liberation of active MP58 from the prodrug and marking of tumor cells for CTL lysis. These results demonstrate that immunogenic peptide prodrugs are novel agents with therapeutic potential for solid tumors.